

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
24 January 2002 (24.01.2002)

PCT

(10) International Publication Number  
WO 02/06460 A2

(51) International Patent Classification<sup>7</sup>: C12N 9/64,  
15/12, C07K 14/47, 16/18, G01N 33/573

(21) International Application Number: PCT/DK01/00499

(22) International Filing Date: 13 July 2001 (13.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
PA 2000 01089 13 July 2000 (13.07.2000) DK  
PA 2001 00870 1 June 2001 (01.06.2001) DK

(71) Applicants and

(72) Inventors: JENSENIUS, Jens, Christian [DK/DK]; Fin-  
sens Allé 28, DK-5230 Odense (DK). THIEL, Steffen  
[DK/DK]; Nordtoftevej 11, DK-8240 Risskov (DK).

(74) Agent: HØIBERG APS; St. Kongensgade 59B, DK-1264  
Copenhagen K (DK).

(81) Designated States (national): AE, AG, AL, AM, AT, AT  
(utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA,

CH, CN, CO, CR, CU, CZ, CZ (utility model), DE, DE  
(utility model), DK, DK (utility model), DM, DZ, EC, EE,  
EE (utility model), ES, FI, FI (utility model), GB, GD, GE,  
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,  
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,  
MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,  
SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG,  
US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished  
upon receipt of that report
- with sequence listing part of description published sepa-  
rately in electronic form and available upon request from  
the International Bureau

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: MASP-2, A COMPLEMENT-FIXING ENZYME, AND USES FOR IT

(57) Abstract: The present invention relates to substantially pure mannin-binding lectin associated serine protease-2 (MASP-2) polypeptides and fragments thereof as well as nucleic acids encoding such polypeptides. Furthermore, the present invention relates to uses of a substantially pure polypeptide comprising amino acid sequences derived from mannan-binding lectin associated serine protease-2 (MASP2) or a functional homologue thereof for the production of a pharmaceutical composition as well as pharmaceutical compositions comprising MASP-2 and/or MASP-2 fragments. In addition the present invention relates to inhibitors of MASP-2 and pharmaceutical compositions comprising such inhibitors. Methods for detecting MASP-2 nucleic acid expression are included in the invention.

WO 02/06460 A2

BEST AVAILABLE COPY

MASP-2, A COMPLEMENT-FIXING ENZYME, AND USES FOR ITField of the Invention

5 The invention is in the general field of innate pathways for complement fixation involving mannan-binding lectin (MBL), also termed mannan binding protein.

Background of the Invention

10 The complement system comprises a complex array of enzymes and non-enzymatic proteins of importance to the function of the innate as well as the adaptive immune defense<sup>1</sup>. Until recently two modes of activation were known, the classical pathway initiated by antibody-antigen complexes and the alternative pathway initiated by certain structures on microbial surfaces. A third, novel antibody-independent pathway of complement activation has been described<sup>2</sup>. This pathway is initiated when mannan-binding lectin (MBL, first described as mannan-binding protein, MBP, see Ezekowitz, U.S. Patent 5,270,199) binds to carbohydrates.

15 MBL is structurally related to the C1q subcomponent of component C1 of complement, and it appears that MBL activates the complement system via an associated serine protease termed MASP<sup>4</sup> or p100<sup>5</sup>, which is similar to the C1r and C1s components of the classical pathway. The new complement activation pathway is called the MBLectin pathway. According to the mechanism postulated for this pathway, MBL binds to specific carbohydrate structures found on the surface of a range of microorganisms including bacteria, yeast, parasitic protozoa and viruses<sup>6</sup>, and its antimicrobial activity results from activation of the terminal, lytic complement pathway components<sup>7</sup> or promoting phagocytosis<sup>8</sup>.

25 Reportedly, the level of MBL in plasma may be genetically determined<sup>9,10,11</sup>. MBL deficiency is associated with susceptibility to frequent infections with a variety of microorganisms in childhood<sup>12,13</sup>, and, possibly, in adults<sup>13,14</sup>. Recent information associates MBL deficiency with HIV infection and with more rapid death following development of AIDS<sup>15,16</sup>. MBL binds to the a galactosyl form of IgG (G0), which is found at elevated concentrations in rheumatoid arthritis patients, and then activates complement<sup>17</sup>. MBL deficiency is also associated with a predisposition to recurrent spontaneous abortions<sup>18</sup>, and also to development of systemic lupus erythematosus<sup>19</sup>.

30 In the first clinical reconstitution trial, an infant MBL-deficient girl suffering from recurrent infections was apparently cured by injections with purified MBL<sup>20</sup>. For a recent review on MBL, see ref. 6.

35 Relatively high frequencies of MBL mutations associated with MBL-deficiency have been reported in all populations studied. This observation has led to

the hypothesis that MBL may, in certain cases, render the individual more susceptible to certain intracellular infectious agents exploiting MBL to gain access to the target tissues<sup>21</sup>. Since MBL is a very powerful activator of the complement system, it may also be that inexpedient activation through microbial carbohydrates or endotoxins can lead to damaging inflammatory responses<sup>10</sup>. Thus, the overall survival of a population may benefit from the wide individual range of MBL concentrations.

MASP-1 (MBP-associated serine protease, MASP) is a serine protease similar in structure to C1r and C1s of the complement pathway although it has a histidine loop structure of the type found in trypsin and trypsin-like serine proteases. MASP-1 has been found to be involved in complement activation by MBL. A cDNA clone encoding MASP-1 has been reported that encodes a putative leader peptide of 19 amino acids followed by 680 amino acid residues predicted to form the mature peptide.

An abstract reports the existence of a second MASP, termed MASP-2.<sup>22</sup>.

#### Summary of the Invention

The present invention relates to uses of a substantially pure polypeptide comprising amino acid sequences derived from mannan-binding lectin associated serine protease-2 (MASP2)(SEQ ID. 2) or a functional homologue thereof for the production of a pharmaceutical composition.

The invention relates to the isolation and characterization of a mannan-binding lectin (MBL) associated serine protease (MASP-2). MASP-2 shows some homology with the previously reported MASP (MASP-1) and the two C1q-associated serine proteases, C1r and C1s. MBL alone does not provide a functional MBlectin pathway of complement activation.

We have cloned and sequenced the cDNA encoding MASP-2. In addition, we have produced anti-MASP-2 antibody and constructed an assay for the estimation of MASP-2 in body fluids or tissue extracts. Furthermore, we have constructed quantitative assays for the determination of MASP-2 activity in serum or plasma, either when present as part of the MBL/MASP complex or as free MASP not associated with MBL.

Thus, one aspect of the invention features substantially pure mannin-binding lectin associated serine protease-2 (MASP-2) polypeptides and nucleic acids encoding such polypeptides. Preferably, the MASP-2 polypeptide retains one or more

MASP-2 functions, such as being capable of associating with mannan-binding lectin (MBL), serine protease activity, or the MASP-2 activity in an *in vitro* assay for MBLectin complement pathway function, e.g., in one of the assay systems described below. Some MASP-2 polypeptides according to the invention, e.g., those used in binding assays, may be conjugated to a label so as to permit detection and/or quantification of their presence in the assay. Suitable labels include enzymes which generate a signal (e.g., visible absorption), fluorophores, radionuclides, etc. Other MASP-2 polypeptides are capable of competitively inhibiting one of the MASP-2 activities described above, and thereby are useful in evaluating MASP-2 function. Other MASP-2 polypeptides are useful antigens or haptens for producing antibodies as described below. Compounds which competitively inhibit a MASP-2 activity are also featured. Preferably, such compounds act by inhibiting the serine protease activity of MASP-2 or of a fragment of MASP-2. Such compounds may include fragments of MBL or of MASP-2 which competitively inhibit the MBL-MASP-2 interactions critical to complement activation by the MBLectin pathway, as well as compounds, e.g., peptide fragments, which inhibit the catalytic cleavage of complement factors C4 and C2 by MASP-2.

Specific polypeptides according to this aspect of the invention include: a) a polypeptide with a molecular mass of 20K and containing the sequence identified as SEQ ID NO:1 [T P L G P K W P E P V F G R L A S P G F P G E Y A N D Q E R R W T L T A P P G Y R]; b) a polypeptide with a molecular mass of 52K and containing the sequence identified as SEQ ID NO:1; c) a polypeptide having the complete amino acid sequence of Fig. 6 (SEQ ID NO:2).

Another aspect of the invention includes an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having sequence that is at least 85% identical to the sequence of SEQ ID NO:2.

The invention also features isolated nucleic acid sequences encoding the above mannan-binding lectin associated serine protease-2 (MASP-2) polypeptides. Such nucleic acid sequences may be included in nucleic acid vectors (e.g., expression vectors including those with regulatory nucleic acid elements permitting expression of recombinant nucleic acid in an expression system).

The invention also features antibodies that selectively bind to MASP-2. Such antibodies may be made by any of the well known techniques including polyclonal and monoclonal antibody techniques. The antibody may be coupled to a compound comprising a detectable marker, so that it can be used, e.g. in an assay to detect MASP-2.



The polypeptides or antibodies may be formulated into pharmaceutical compositions and administered as therapeutics as described below.

The invention also features methods for detecting mannan-binding lectin associated serine protease-2 (MASP-2). The method comprises; obtaining a biological sample, contacting the biological sample with a MASP-2 polypeptide specific binding partner, and detecting the bound complexes, if any, as an indication of the presence of MASP-2 in the biological sample. The binding partner used in the assay may be an antibody, or the assay for MASP-2 may test for complement fixing activity. These assays for MASP-2 may also be used for quantitative assays of MASP-2 or MASP-2 activity in biological samples. One of the binding partners may be specific for MBK thus allowing for the detection of MBL/MASP-2 complexes.

Methods for detecting MASP-2 nucleic acid expression are included in the invention. These methods comprise detecting RNA having a sequence encoding a MASP-2 polypeptide by mixing the sample with a nucleic acid probe that specifically hybridizes under stringent conditions to a nucleic acid sequence encoding all or a fragment of MASP-2.

The invention also features methods for treating patients deficient in MASP-2 or MASP-2 activity. This is accomplished by administering to the patient MASP-2 polypeptide or nucleic acid encoding MASP-2. Because it is sometimes desirable to inhibit MASP-2 activity, the invention includes a method for inhibiting the activity of MASP-2 by administering to the patient a compound that inhibits expression or activity of MASP-2. Inhibition of MASP-2 activity may also be achieved by administering a MASP-2 anti-sense nucleic acid sequence.

The invention features an assay for polymorphisms in the nucleic acid sequence encoding MASP-2. A method of detecting the presence of MASP-2-encoding nucleic acid in a sample is claimed. As an example, the method may include mixing the sample with at least one nucleic acid probe capable of forming a complex with MASP-2-encoding nucleic acid under stringent conditions, and determining whether the probe is bound to sample nucleic acid. The invention thus includes nucleic acid probe capable of forming a complex with MASP-2-encoding nucleic acid under stringent conditions.

The invention features an assay for polymorphisms in the polypeptide sequence comprising MASP-2 or its precursor.

MASP-2 assays are useful for the determination of MASP-2 levels and MASP-2 activity in patients suffering from various diseases such as infections,

inflammatory diseases and spontaneous recurrent abortion. MASP-2 is useful for the treatment of infections when MASP-2 function is suboptimal, and inhibition of MASP-2 activity is useful for regulation of inflammation and adverse effects caused by activity of the MBlectin pathway.

5 By "mannan-binding lectin associated serine protease-2" or "MASP-2" is meant the polypeptide or activity called "mannan-binding protein associated serine protease-2" or "mannose-binding protein associated serine protease" or any other polypeptide having substantial sequence identity with SEQ ID NO:2.

10 The terms "protein" and "polypeptide" are used herein to describe any chain of amino acids, regardless of length or post-translational modification (for example, glycosylation or phosphorylation). Thus, the term "MASP-2 polypeptide" includes full-length, naturally occurring MASP-2 protein, as well as recombinantly or synthetically produced polypeptide that corresponds to a full-length naturally occurring MASP-2 polypeptide, or to particular domains or portions of a naturally occurring  
15 protein. The term also encompasses mature MASP-2 which has an added amino-terminal methionine (which is useful for expression in prokaryotic cells).

The term "purified" as used herein refers to a nucleic acid or peptide that is substantially free of cellular material, viral material, or culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when  
20 chemically synthesized. By "isolated nucleic acid molecule" is meant a nucleic acid molecule that is separated in any way from sequences in the naturally occurring genome of an organism. Thus, the term "isolated nucleic acid molecule" includes nucleic acid molecules which are not naturally occurring, e.g., nucleic acid molecules created by recombinant DNA techniques.

25 The term "nucleic acid molecule" encompasses both RNA and DNA, including cDNA, genomic DNA, and synthetic (e.g., chemically synthesized) DNA. Where single-stranded, the nucleic acid may be a sense strand or an antisense strand.

The invention also encompasses nucleic acid molecules that hybridize, preferably under stringent conditions, to a nucleic acid molecule encoding an MASP-2 polypeptide (e.g., a nucleic acid molecule having the sequence encoding SEQ ID  
30 NO:2, e.g., the protein encoding portion of the cDNA sequence shown in Fig. 6). In addition, the invention encompasses nucleic acid molecules that hybridize, preferably under stringent conditions, to a nucleic acid molecule having the sequence of the MASP-2 encoding cDNA contained in a clone. Preferably the hybridizing nucleic acid  
35 molecule consists of 400, more preferably 200 nucleotides.

Preferred hybridizing nucleic acid molecules encode an activity possessed by MASP-2, e.g., they bind MBL and have activity in the MBLectin complement pathway, and can act as serine proteases.

5                    Throughout the description and claims either the three letter code or the one-letter code for natural amino acids are used. Where the L or D form has not been specified it is to be understood that the amino acid in question has the natural L form, cf. Pure & Appl. Chem. Vol. (56(5) pp 595-624 (1984) or the D form, so that the peptides formed may be constituted of amino acids of L form, D form, or a sequence of mixed L forms and D forms. Where nothing is specified it is to be understood that the C-terminal amino acid of a polypeptide of the invention exists as the free carboxylic acid and the N-terminal amino acid of a polypeptide comprise a free amino-group. Where nothing else is specified amino acid can be selected from any amino acid, whether naturally occurring or not, such as alpha amino acids, beta amino acids, and/or gamma amino acids. Accordingly, the group comprises but are not limited to: Ala, Val, Leu, Ile, Pro, Phe, Trp, Met, Gly, Ser, Thr, Cys, Tyr, Asn, Gln, Asp, Glu, Lys, Arg, His, Aib, Nal, Sar, Orn, Lysine analogues DAP and DAPA.

15                    The invention also features substantially pure or isolated MASP-2 polypeptides, preferably those that correspond to various functional domains of MASP-2, or fragments thereof. The polypeptides of the invention encompass amino acid sequences that are substantially identical to the amino acid sequence shown in Fig.6.

20                    The polypeptides of the invention can also be chemically synthesized, synthesized by recombinant technology, or they can be purified from tissues in which they are naturally expressed, according to standard biochemical methods of purification.

25                    Also included in the invention are "functional polypeptides" which possess one or more of the biological functions or activities of MASP-2. These functions or activities are described in detail in the specification. A functional polypeptide is also considered within the scope of the invention if it serves as an antigen for production of antibodies that specifically bind to MASP-2 or fragments (particularly determinant containing fragments) thereof.

30                    The functional polypeptides may contain a primary amino acid sequence that has been modified from those disclosed herein. Preferably these modifications consist of conservative amino acid substitutions, as described herein. The

polypeptides may be substituted in any manner designed to promote or delay their catabolism (increase their half-life).

The terms "functional homologues" and "functional equivalent" are used interchangeably herein and should be understood as synonymous with one another within the scope of the present invention. Functional homologues of polypeptides according to the present invention is meant to comprise any polypeptide sequence which is capable of exerting MASP-2 activity or activity of a MASP-2 fragment, such as for example activity as a competitive inhibitor of MASP-2.

Functional homologues according to the present invention comprise polypeptides with an amino acid sequence, which are sharing at least some homology with the predetermined polypeptide sequences as outlined herein above. For example such polypeptides are at least about 40 percent, such as at least about 50 percent homologous, for example at least about 60 percent homologous, such as at least about 70 percent homologous, for example at least about 75 percent homologous, such as at least about 80 percent homologous, for example at least about 85 percent homologous, such as at least about 90 percent homologous, for example at least 92 percent homologous, such as at least 94 percent homologous, for example at least 95 percent homologous, such as at least 96 percent homologous, for example at least 97 percent homologous, such as at least 98 percent homologous, for example at least 99 percent homologous with the predetermined polypeptide sequences as outlined herein above.

The homology between amino acid sequences may be calculated using well known algorithms such as for example any one of BLOSUM 30, BLOSUM 40, BLOSUM 45, BLOSUM 50, BLOSUM 55, BLOSUM 60, BLOSUM 62, BLOSUM 65, BLOSUM 70, BLOSUM 75, BLOSUM 80, BLOSUM 85, and BLOSUM 90.

Functional homologues may comprise an amino acid sequence that comprises at least one substitution of one amino acid for any other amino acid. For example such a substitution may be a conservative amino acid substitution or it may be a non-conservative substitution.

A conservative amino acid substitution is a substitution of one amino acid within a predetermined group of amino acids for another amino acid within the same group, wherein the amino acids within a predetermined groups exhibit similar or substantially similar characteristics. Within the meaning of the term "conservative amino acid substitution" as applied herein, one amino acid may be substituted for another within groups of amino acids characterised by having

- i) polar side chains (Asp, Glu, Lys, Arg, His, Asn, Gln, Ser, Thr, Tyr, and Cys,)
- ii) non-polar side chains (Gly, Ala, Val, Leu, Ile, Phe, Trp, Pro, and Met)
- iii) aliphatic side chains (Gly, Ala Val, Leu, Ile)
- iv) cyclic side chains (Phe, Tyr, Trp, His, Pro)
- v) aromatic side chains (Phe, Tyr, Trp)
- vi) acidic side chains (Asp, Glu)
- vii) basic side chains (Lys, Arg, His)
- viii) amide side chains (Asn, Gln)
- ix) hydroxy side chains (Ser, Thr)
- x) sulphur-containing side chains (Cys, Met), and
- xi) amino acids being monoamino-dicarboxylic acids or monoamino-monocarboxylic-monoamidocarboxylic acids (Asp, Glu, Asn, Gln).

Non-conservative substitutions are any other substitutions. A non-conservative substitution leading to the formation of a functional homologue would for example i) differ substantially in hydrophobicity, for example a hydrophobic residue (Val, Ile, Leu, Phe or Met) substituted for a hydrophilic residue such as Arg, Lys, Trp or Asn, or a hydrophilic residue such as Thr, Ser, His, Gln, Asn, Lys, Asp, Glu or Trp substituted

for a hydrophobic residue; and/or ii) differ substantially in its effect on polypeptide backbone orientation such as substitution of or for Pro or Gly by another residue; and/or iii) differ substantially in electric charge, for example substitution of a negatively charged residue such as Glu or Asp for a positively charged residue such as Lys, His or Arg (and vice versa); and/or iv) differ substantially in steric bulk, for example substitution of a bulky residue such as His, Trp, Phe or Tyr for one having a minor side chain, e.g. Ala, Gly or Ser (and vice versa).

Functional homologues according to the present invention may comprise more than one such substitution, such as e.g. two amino acid substitutions, for example three or four amino acid substitutions, such as five or six amino acid substitutions, for example seven or eight amino acid substitutions, such as from 10 to 15 amino acid substitutions, for example from 15 to 25 amino acid substitution, such as from 25 to 30 amino acid substitutions, for example from 30 to 40 amino acid substitution, such as from 40 to 50 amino acid substitutions, for example from 50 to 75 amino acid substitution, such as from 75 to 100 amino acid substitutions, for example more than 100 amino acid substitutions.

The addition or deletion of an amino acid may be an addition or deletion of from 2 to 5 amino acids, such as from 5 to 10 amino acids, for example from 10 to 20 amino acids, such as from 20 to 50 amino acids. However, additions or deletions of more than 50 amino acids, such as additions from 50 to 200 amino acids, are also comprised within the present invention.

The polypeptides according to the present invention, including any variants and functional homologues thereof, may in one embodiment comprise more than 5 amino acid residues, such as more than 10 amino acid residues, for example more than 20 amino acid residues, such as more than 25 amino acid residues, for example more than 50 amino acid residues, such as more than 75 amino acid residues, for example more than 100 amino acid residues, such as more than 150 amino acid residues, for example more than 200 amino acid residues.

Additional factors may be taken into consideration when determining functional homologues according to the meaning used herein. For example functional homo-

logues may be capable of associating with antisera which are specific for the polypeptides according to the present invention.

In a further embodiment the present invention relates to functional equivalents which comprise substituted amino acids having hydrophilic or hydrophobic indices that are within  $\pm 2.5$ , for example within  $\pm 2.3$ , such as within  $\pm 2.1$ , for example within  $\pm 2.0$ , such as within  $\pm 1.8$ , for example within  $\pm 1.6$ , such as within  $\pm 1.5$ , for example within  $\pm 1.4$ , such as within  $\pm 1.3$  for example within  $\pm 1.2$ , such as within  $\pm 1.1$ , for example within  $\pm 1.0$ , such as within  $\pm 0.9$ , for example within  $\pm 0.8$ , such as within  $\pm 0.7$ , for example within  $\pm 0.6$ , such as within  $\pm 0.5$ , for example within  $\pm 0.4$ , such as within  $\pm 0.3$ , for example within  $\pm 0.25$ , such as within  $\pm 0.2$  of the value of the amino acid it has substituted.

The importance of the hydrophilic and hydrophobic amino acid indices in conferring interactive biologic function on a protein is well understood in the art (Kyte & Doolittle, 1982 and Hopp, U.S. Pat. No. 4,554,101, each incorporated herein by reference).

The amino acid hydrophobic index values as used herein are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5) (Kyte & Doolittle, 1982).

The amino acid hydrophilicity values are: arginine (+3.0); lysine (+3.0); aspartate (+3.0 $\pm$ 1); glutamate (+3.0 $\pm$ 1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5 $\pm$ 1); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4) (U.S. 4,554,101).

Substitution of amino acids can therefore in one embodiment be made based upon their hydrophobicity and hydrophilicity values and the relative similarity of the amino acid side-chain substituents, including charge, size, and the like. Exemplary amino acid substitutions which take various of the foregoing characteristics into considera-

tion are well known to those of skill in the art and include: arginine and lysine; glutamate and aspartate; serine and threonine; glutamine and asparagine; and valine, leucine and isoleucine.

5 In addition to the polypeptide compounds described herein, sterically similar compounds may be formulated to mimic the key portions of the peptide structure and that such compounds may also be used in the same manner as the peptides of the invention. This may be achieved by techniques of modelling and chemical designing known to those of skill in the art. For example, esterification and other alkylations  
10 may be employed to modify the amino terminus of, e.g., a di-arginine peptide backbone, to mimic a tetra peptide structure. It will be understood that all such sterically similar constructs fall within the scope of the present invention.

Peptides with N-terminal alkylations and C-terminal esterifications are also encompassed within the present invention. Functional equivalents also comprise glycosylated and covalent or aggregative conjugates, including dimers or unrelated chemical  
15 moieties. Such functional equivalents are prepared by linkage of functionalities to groups which are found in fragment including at any one or both of the N- and C-termini, by means known in the art.

20 Functional equivalents may thus comprise fragments conjugated to aliphatic or acyl esters or amides of the carboxyl terminus, alkylamines or residues containing carboxyl side chains, e.g., conjugates to alkylamines at aspartic acid residues; O-acyl derivatives of hydroxyl group-containing residues and N-acyl derivatives of the  
25 amino terminal amino acid or amino-group containing residues, e.g. conjugates with Met-Leu-Phe. Derivatives of the acyl groups are selected from the group of alkylmoieties (including C3 to C10 normal alkyl), thereby forming alkanoyl species, and carbocyclic or heterocyclic compounds, thereby forming aroyl species. The reactive groups preferably are difunctional compounds known per se for use in cross-linking  
30 proteins to insoluble matrices through reactive side groups.

Homologues of nucleic acid sequences within the scope of the present invention are nucleic acid sequences, which encodes an RNA and/or a protein with similar biological function, and which is either  
35



- a) at least 50% identical, such as at least 60% identical, for example at least 70% identical, such as at least 75% identical, for example at least 80% identical, such as at least 85% identical, for example at least 90% identical, such as at least 95% identical
- 5 b) or able to hybridise to the complementary strand of said nucleic acid sequence under stringent conditions.

Stringent conditions as used herein shall denote stringency as normally applied in connection with Southern blotting and hybridisation as described e.g. by Southern E. M., 1975, J. Mol. Biol. 98:503-517. For such purposes it is routine practise to include steps of prehybridization and hybridization. Such steps are normally performed using solutions containing 6x SSPE, 5% Denhardt's, 0.5% SDS, 50% formamide, 100 g/ml denaturated salmon testis DNA (incubation for 18 hrs at 42°C), followed by washings with 2x SSC and 0.5% SDS (at room temperature and at 37°C), and a washing with 0.1x SSC and 0.5% SDS (incubation at 68°C for 30 min), as described by Sambrook et al., 1989, in "Molecular Cloning/A Laboratory Manual", Cold Spring Harbor), which is incorporated herein by reference.

Homologous of nucleic acid sequences also encompass nucleic acid sequences which comprise additions and/or deletions. Such additions and/or deletions may be internal or at the end. Additions and/or deletions may be of 1-5 nucleotides, such as 5 to 10 nucleotide, for example 10 to 50 nucleotides, such as 50 to 100 nucleotides, for example at least 100 nucleotides.

Polypeptides or other compounds of interest are said to be "substantially pure" when they are distinct from any naturally occurring composition, and suitable for at least one of the uses proposed herein. While preparations that are only slightly altered with respect to naturally occurring substances may be somewhat useful, more typically, the preparations are at least 10% by weight (dry weight) the compound of interest. Preferably, the preparation is at least 60%, more preferably at least 75%, and most preferably at least 90%, by weight the compound of interest. Purity can be measured by any appropriate standard method, for example, by column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.

A polypeptide or nucleic acid molecule is "substantially identical" to a reference polypeptide or nucleic acid molecule if it has a sequence that is at least 85%,

preferably at least 90%, and more preferably at least 95%, 98%, or 99% identical to the sequence of the reference polypeptide or nucleic acid molecule.

Where a particular polypeptide is said to have a specific percent identity to a reference polypeptide of a defined length, the percent identity is relative to the reference peptide. Thus, a peptide that is 50% identical to a reference polypeptide that is 100 amino acids long can be a 50 amino acid polypeptide that is completely identical to a 50 amino acid long portion of the reference polypeptide. It might also be a 100 amino acid long polypeptide which is 50% identical to the reference polypeptide over its entire length. Of course, many other polypeptides will meet the same criteria.

In the case of polypeptide sequences which are less than 100% identical to a reference sequence, the non-identical positions are preferably, but not necessarily, conservative substitutions for the reference sequence. Conservative substitutions typically include substitutions within the following groups: glycine and alanine; valine, isoleucine, and leucine; aspartic acid and glutamic acid; asparagine and glutamine; serine and threonine; lysine and arginine; and phenylalanine and tyrosine.

For polypeptides, the length of the reference polypeptide sequence will generally be at least 16 amino acids, preferably at least 20 amino acids, more preferably at least 25 amino acids, and most preferably 35 amino acids, 50 amino acids, or 100 amino acids. For nucleic acids, the length of the reference nucleic acid sequence will generally be at least 50 nucleotides, preferably at least 60 nucleotides, more preferably at least 75 nucleotides, and most preferably 100 nucleotides or 300 nucleotides.

Sequence identity can be measured using sequence analysis software (for example, the Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705), with the default parameters as specified therein.

The nucleic acid molecules of the invention can be inserted into a vector, as described below, which will facilitate expression of the insert. The nucleic acid molecules and the polypeptides they encode can be used directly as diagnostic or therapeutic agents, or can be used (directly in the case of the polypeptide or indirectly in the case of a nucleic acid molecule) to generate antibodies that, in turn, are clinically useful as a therapeutic or diagnostic agent. Accordingly, vectors containing the nucleic acid of the invention, cells transfected with these vectors, the polypeptides expressed, and antibodies generated, against either the entire polypeptide or an antigenic fragment thereof, are among the preferred embodiments.

The invention also features antibodies, e.g., monoclonal, polyclonal, and engineered antibodies, which specifically bind MASP-2. By "specifically binds" is meant an antibody that recognizes and binds to a particular antigen, e.g., the MASP-2 polypeptide of the invention, but which does not substantially recognize or bind to other molecules in a sample, e.g., a biological sample, which includes MASP-2. References to constructs of antibody (or fragment thereof) coupled to a compound comprising a detectable marker includes constructs made by any technique, including chemical means or by recombinant techniques. The invention also features compounds capable of inhibiting activity of MASP-2 or a functional homologue thereof. One activity of MASP-2 is to aid complement activation. Another activity of MASP-2 is the serine protease activity of MASP-2. Preferably, compounds capable of inhibiting activity of MASP-2 are capable of inhibiting complement activation by MASP-2. It is important to realise that only a minor proportion of MASP's are associated with MBL in serum. Accordingly, a compound capable of inhibiting MASP-2 activity may exert an inhibitory effect on the complement activation by associating with MBL without activating MBL, and so depleting serum of active MASP-MBL complexes. The compound may be a fragment of MASP-2 or it may be a mutant of MASP-2 or a fragment of a mutant of MASP-2. Furthermore, the compound may be an antibody.

The invention also features antagonists and agonists of MASP-2 that can inhibit or enhance one or more of the functions or activities of MASP-2, respectively. Suitable antagonists can include small molecules (i.e., molecules with a molecular weight below about 500), large molecules (i.e., molecules with a molecular weight above about 500), antibodies that bind and "neutralize" MASP-2 (as described below), polypeptides which compete with a native form of MASP-2 for binding to a protein, e.g., MBL, and nucleic acid molecules that interfere with transcription of MASP-2 (for example, antisense nucleic acid molecules and ribozymes). Agonists of MASP-2 also include small and large molecules, and antibodies other than "neutralizing" antibodies.

The invention also features molecules which can increase or decrease the expression of MASP-2 (e.g., by influencing transcription or translation). Small molecules (i.e., molecules with a molecular weight below about 500), large molecules (i.e., molecules with a molecular weight above about 500), and nucleic acid molecules that can be used to inhibit the expression of MASP-2 (for example, antisense and ribozyme molecules) or to enhance their expression (for example, expression constructs that place nucleic acid sequences encoding MASP-2 under the control of a strong promoter system), and transgenic animals that express a MASP-2 transgene.

The invention encompasses methods for treating disorders associated with aberrant expression or activity of MASP-2. Thus, the invention includes methods for treating disorders associated with excessive expression or activity of MASP-2. Such methods entail administering a compound which decreases the expression or activity of MASP-2. The invention also includes methods for treating disorders associated with insufficient expression of MASP-2. These methods entail administering a compound which increases the expression or activity of MASP-2.

By "competitively inhibiting" serine protease activity is meant that, for example, the action of an altered MBL or fragment thereof that can bind to a MASP-2 peptide, reversibly or irreversibly without activating serine protease activity. Conversely, a fragment of MASP-2, e.g., a polypeptide encompassing the N-terminal part of MASP-2, may competitively inhibit the binding of the intact MASP-2 and thus effectively inhibit the activation of MASP-2.

The invention also features methods for detecting a MASP-2 polypeptide. Such methods include: obtaining a biological sample; contacting the sample with an antibody that specifically binds MASP-2 under conditions which permit specific binding; and detecting any antibody-MASP-2 complexes formed.

In addition, the present invention encompasses methods and compositions for the diagnostic evaluation, typing, and prognosis of disorders associated with inappropriate expression or activity of MASP-2. For example, the nucleic acid molecules of the invention can be used as diagnostic hybridization probes to detect, for example, inappropriate expression of MASP-2 or mutations in the MASP-2 gene. Such methods may be used to classify cells by the level of MASP-2 expression.

Alternatively, the nucleic acid molecules can be used as primers for diagnostic PCR analysis for the identification of gene mutations, allelic variations and regulatory defects in the MASP-2 gene. The present invention further provides for diagnostic kits for the practice of such methods.

The invention features methods of identifying compounds that modulate the expression or activity of MASP-2 by assessing the expression or activity of MASP-2 in the presence and absence of a selected compound. A difference in the level of expression or activity of MASP-2 in the presence and absence of the selected compound indicates that the selected compound is capable of modulating expression or activity of MASP-2. Expression can be assessed either at the level of gene expression (e.g., by measuring mRNA) or protein expression by techniques that are

well known to skilled artisans. The activity of MASP-2 can be assessed functionally, i.e., by assaying the ability of the compound to activate complement.

The preferred methods and materials are described below in examples which are meant to illustrate, not limit, the invention. Skilled artisans will recognize methods and materials that are similar or equivalent to those described herein, and that can be used in the practice or testing of the present invention.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described herein. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be limiting.

Other features and advantages of the invention will be apparent from the detailed description, and from the claims.

#### Brief Description of the Drawings

Figures 1a-1b depict a Western blot of human plasma proteins purified by sugar affinity chromatography.

Figure 2 shows the sequence alignment<sup>21</sup> of the amino acid sequences of MASP-2 (clone phi-4), MASP-1<sup>17,22</sup>, C1r<sup>23,24</sup> and C1s<sup>25,26</sup>.

Figures 3a-3b are representations of the results demonstrating molecular complexes formed between MBL, MASP-1 and MASP-2.

Figures 4a-4b are representations of Western blots demonstrating the activation of C4 by C1s and MASP-2.

Figure 5 illustrates the three pathways of complement activation.

Figure 6 shows the cDNA sequence and deduced amino acid sequence of MASP-2.

#### Brief description of sequence listing

SEQ ID 1: Amino acid sequence of 20 kD MASP-2 fragment

SEQ ID 2: Amino acid sequence of full length MASP-2 including the signal peptide

SEQ ID 3: Amino acid sequence of full length MASP-2 without the signal peptide

5

Description of the Preferred Embodiments

*MASP-2 nucleic acid molecules*

10 The MASP-2 nucleic acid molecules of the invention can be cDNA, genomic DNA, synthetic DNA, or RNA, and can be double-stranded or single-stranded (*i.e.*, either a sense or an antisense strand). Fragments of these molecules are also considered within the scope of the invention, and can be produced, for example, by the polymerase chain reaction (PCR) or generated by treatment with one or more restriction endonucleases. A ribonucleic acid (RNA) molecule can be produced by  
15 *in vitro* transcription. Preferably, the nucleic acid molecules encode polypeptides that, regardless of length, are soluble under normal physiological conditions.

The nucleic acid molecules of the invention can contain naturally occurring sequences, or sequences that differ from those that occur naturally, but, due to the degeneracy of the genetic code, encode the same polypeptide (for example, the  
20 polypeptide of SEQ ID NO:2). In addition, these nucleic acid molecules are not limited to sequences that only encode polypeptides, and thus, can include some or all of the non-coding sequences that lie upstream or downstream from a coding sequence.

The nucleic acid molecules of the invention can be synthesized (for example, by phosphoramidite-based synthesis) or obtained from a biological cell, such  
25 as the cell of a mammal. Thus, the nucleic acids can be those of a human, mouse, rat, guinea pig, cow, sheep, horse, pig, rabbit, monkey, dog, or cat. Combinations or modifications of the nucleotides within these types of nucleic acids are also encompassed.

In addition, the isolated nucleic acid molecules of the invention encompass  
30 fragments that are not found as such in the natural state. Thus, the invention encompasses recombinant molecules, such as those in which a nucleic acid molecule (for example, an isolated nucleic acid molecule encoding MASP-2) is incorporated into a vector (for example, a plasmid or viral vector) or into the genome of a heterologous cell (or the genome of a homologous cell, at a position other than the natural

chromosomal location). Recombinant nucleic acid molecules and uses therefore are discussed further below.

In the event the nucleic acid molecules of the invention encode or act as antisense molecules, they can be used for example, to regulate translation of MASP-2. Techniques associated with detection or regulation of nucleic acid expression are well known to skilled artisans and can be used to diagnose and/or treat disorders associated with MASP-2 activity. These nucleic acid molecules are discussed further below in the context of their clinical utility.

The invention also encompasses nucleic acid molecules that hybridize under stringent conditions to a nucleic acid molecule encoding a MASP-2 polypeptide. The cDNA sequence described herein (SEQ ID NO:3) can be used to identify these nucleic acids, which include, for example, nucleic acids that encode homologous polypeptides in other species, and splice variants of the MASP-2 gene in humans or other mammals. Accordingly, the invention features methods of detecting and isolating these nucleic acid molecules. Using these methods, a sample (for example, a nucleic acid library, such as a cDNA or genomic library) is contacted (or "screened") with a MASP-2-specific probe (for example, a fragment of the cDNA sequence depicted in figure 6 encoding the polypeptide sequence SEQ ID NO. 2, that is at least 12 nucleotides long). The probe will selectively hybridize to nucleic acids encoding related polypeptides (or to complementary sequences thereof). Because the polypeptide encoded by MASP-2 is related to other serine proteases, the term "selectively hybridize" is used to refer to an event in which a probe binds to nucleic acids encoding MASP-2 (or to complementary sequences thereof) to a detectably greater extent than to nucleic acids encoding other serine proteases (or to complementary sequences thereof). The probe, which can contain at least 12 (for example, 15, 25, 50, 100, or 200 nucleotides) can be produced using any of several standard methods (see, for example, Ausubel et al., "Current Protocols In Molecular Biology, Vol. I," Green Publishing Associates, Inc., and John Wiley & Sons, Inc., NY, 1989). For example, the probe can be generated using PCR amplification methods in which oligonucleotide primers are used to amplify a MASP-2-specific nucleic acid sequence (for example, a nucleic acid encoding the N-terminus of mature MASP-2) that can be used as a probe to screen a nucleic acid library, as described in Example 4 below, and thereby detect nucleic acid molecules (within the library) that hybridize to the probe.

One single-stranded nucleic acid is said to hybridize to another if a duplex forms between them. This occurs when one nucleic acid contains a sequence that is

the reverse and complement of the other (this same arrangement gives rise to the natural interaction between the sense and antisense strands of DNA in the genome and underlies the configuration of the "double helix"). Complete complementarity between the hybridizing regions is not required in order for a duplex to form; it is only  
5 necessary that the number of paired bases is sufficient to maintain the duplex under the hybridization conditions used.

Typically, hybridization conditions are of low to moderate stringency. These conditions favor specific interactions between completely complementary sequences, but allow some non-specific interaction between less than perfectly  
10 matched sequences to occur as well. After hybridization, the nucleic acids can be "washed" under moderate or high conditions of stringency to dissociate duplexes that are bound together by some non-specific interaction (the nucleic acids that form these duplexes are thus not completely complementary).

As is known in the art, the optimal conditions for washing are determined  
15 empirically, often by gradually increasing the stringency. The parameters that can be changed to affect stringency include, primarily, temperature and salt concentration. In general, the lower the salt concentration and the higher the temperature, the higher the stringency. Washing can be initiated at a low temperature (for example, room temperature) using a solution containing a salt concentration that is equivalent to or  
20 lower than that of the hybridization solution. Subsequent washing can be carried out using progressively warmer solutions having the same salt concentration. As alternatives, the salt concentration can be lowered and the temperature maintained in the washing step, or the salt concentration can be lowered and the temperature increased. Additional parameters can also be altered. For example, use of a  
25 destabilizing agent, such as formamide, alters the stringency conditions.

In reactions where nucleic acids are hybridized, the conditions used to achieve a given level of stringency will vary. There is not one set of conditions, for example, that will allow duplexes to form between all nucleic acids that are 85% identical to one another; hybridization also depends on unique features of each  
30 nucleic acid. The length of the sequence, the composition of the sequence (for example, the content of purine-like nucleotides versus the content of pyrimidine-like nucleotides) and the type of nucleic acid (for example, DNA or RNA) affect hybridization. An additional consideration is whether one of the nucleic acids is immobilized (for example, on a filter).



An example of a progression from lower to higher stringency conditions is the following, where the salt content is given as the relative abundance of SSC (a salt solution containing sodium chloride and sodium citrate; 2X SSC is 10-fold more concentrated than 0.2X SSC). Nucleic acids are hybridized at 42°C in 2X SSC/0.1% SDS (sodium dodecylsulfate; a detergent) and then washed in 0.2X SSC/0.1% SDS at room temperature (for conditions of low stringency); 0.2X SSC/0.1% SDS at 42°C (for conditions of moderate stringency); and 0.1X SSC at 68°C (for conditions of high stringency). Washing can be carried out using only one of the conditions given, or each of the conditions can be used (for example, washing for 10-15 minutes each in the order listed above). Any or all of the washes can be repeated. As mentioned above, optimal conditions will vary and can be determined empirically.

A second set of conditions that are considered "stringent conditions" are those in which hybridization is carried out at 50°C in Church buffer (7% SDS, 0.5% NaHPO<sub>4</sub>, 1 M EDTA, 1% bovine serum albumin) and washing is carried out at 50°C in 2X SSC.

Once detected, the nucleic acid molecules can be isolated by any of a number of standard techniques (see, for example, Sambrook et al., "Molecular Cloning, A Laboratory Manual," 2nd Ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).

The invention also encompasses: (a) expression vectors that contain any of the foregoing MASP-2-related coding sequences and/or their complements (that is, "antisense" sequence); (b) expression vectors that contain any of the foregoing MASP-2-related coding sequences operatively associated with a regulatory element (examples of which are given below) that directs the expression of the coding sequences; (c) expression vectors containing, in addition to sequences encoding a MASP-2 polypeptide, nucleic acid sequences that are unrelated to nucleic acid sequences encoding MASP-2, such as molecules encoding a reporter or marker; and (d) genetically engineered host cells that contain any of the foregoing expression vectors and thereby express the nucleic acid molecules of the invention in the host cell.

Recombinant nucleic acid molecule can contain a sequence encoding a soluble MASP-2, mature MASP-2, MASP-2 having a signal sequence, or functional domains of MASP-2 such as the serine protease domain, EGF domain, or the MBL-binding domain. The full length MASP-2 polypeptide, a domain of MASP-2, or a fragment thereof may be fused to additional polypeptides, as described below.

Similarly, the nucleic acid molecules of the invention can encode the mature form of MASP-2 or a form that encodes a polypeptide which facilitates secretion. In the latter instance, the polypeptide is typically referred to as a proprotein, which can be converted into an active form by removal of the signal sequence, for example, within the host cell. Proproteins can be converted into the active form of the protein by removal of the inactivating sequence.

The regulatory elements referred to above include, but are not limited to, inducible and non-inducible promoters, enhancers, operators and other elements, which are known to those skilled in the art, and which drive or otherwise regulate gene expression. Such regulatory elements include but are not limited to the cytomegalovirus hCMV immediate early gene, the early or late promoters of SV40 adenovirus, the lac system, the trp system, the TAC system, the TRC system, the major operator and promoter regions of phage A, the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase, the promoters of acid phosphatase, and the promoters of the yeast  $\alpha$ -mating factors.

Similarly, the nucleic acid can form part of a hybrid gene encoding additional polypeptide sequences, for example, sequences that function as a marker or reporter. Examples of marker or reporter genes include  $\beta$ -lactamase, chloramphenicol acetyltransferase (CAT), adenosine deaminase (ADA), aminoglycoside phosphotransferase (neo<sup>r</sup>, G418<sup>r</sup>), dihydrofolate reductase (DHFR), hygromycin-B-phosphotransferase (HPH), thymidine kinase (TK), lacZ (encoding  $\beta$ -galactosidase), green fluorescent protein (GFP), and xanthine guanine phosphoribosyltransferase (XGPRT). As with many of the standard procedures associated with the practice of the invention, skilled artisans will be aware of additional useful reagents, for example, of additional sequences that can serve the function of a marker or reporter. Generally, the hybrid polypeptide will include a first portion and a second portion; the first portion being a MASP-2 polypeptide and the second portion being, for example, the reporter described above or an immunoglobulin constant region.

The expression systems that may be used for purposes of the invention include, but are not limited to, microorganisms such as bacteria (for example, *E. coli* and *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA, or cosmid DNA expression vectors containing the nucleic acid molecules of the invention; yeast (for example, *Saccharomyces* and *Pichia*) transformed with recombinant yeast expression vectors containing the nucleic acid molecules of the invention (preferably containing the nucleic acid sequence of MASP-2 (SEQ ID NO:3)); insect cell systems

infected with recombinant virus expression vectors (for example, baculovirus) containing the nucleic acid molecules of the invention; plant cell systems infected with recombinant virus expression vectors (for example, cauliflower mosaic virus (CaMV) and tobacco mosaic virus (TMV)) or transformed with recombinant plasmid expression  
5 vectors (for example, Ti plasmid) containing MASP-2 nucleotide sequences; or mammalian cell systems (for example, COS, CHO, BHK, 293, VERO, HeLa, MDCK, WI38, and NIH 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (for example, the metallothionein promoter) or from mammalian viruses (for example, the adenovirus late promoter and the vaccinia virus 7.5K promoter).  
10

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the gene product being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions containing MASP-2 polypeptides or for  
15 raising antibodies to those polypeptides, vectors that are capable of directing the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited to, the *E. coli* expression vector pUR278 (Ruther et al., *EMBO J.* 2:1791, 1983), in which the coding sequence of the insert may be ligated individually into the vector in frame with the lacZ coding region so  
20 that a fusion protein is produced; pIN vectors (Inouye and Inouye, *Nucleic Acids Res.* 13:3101-3109, 1985; Van Heeke and Schuster, *J. Biol. Chem.* 264:5503-5509, 1989); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX  
25 vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

In an insect system, *Autographa californica* nuclear polyhidrosis virus (AcNPV) can be used as a vector to express foreign genes. The virus grows in  
30 *Spodoptera frugiperda* cells. The coding sequence of the insert may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter). Successful insertion of the coding sequence will result in inactivation of the polyhedrin gene and production of non-occluded recombinant virus (i.e., virus lacking  
35 the proteinaceous coat coded for by the polyhedrin gene). These recombinant viruses

are then used to infect *Spodoptera frugiperda* cells in which the inserted gene is expressed. (for example, see Smith et al., *J. Virol.* 46:584, 1983; Smith, U.S. Patent No. 4,215,051).

5 In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the nucleic acid molecule of the invention may be ligated to an adenovirus transcription/translation control complex, for example, the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by *in vitro* or *in vivo* recombination. Insertion in a non-essential region of the viral genome (for example, 10 region E1 or E3) will result in a recombinant virus that is viable and capable of expressing a MASP-2 gene product in infected hosts (for example, see Logan and Shenk, *Proc. Natl. Acad. Sci. USA* 81:3655-3659, 1984). Specific initiation signals may also be required for efficient translation of inserted nucleic acid molecules. These signals include the ATG initiation codon and adjacent sequences. In cases where an 15 entire gene or cDNA, including its own initiation codon and adjacent sequences, is inserted into the appropriate expression vector, no additional translational control signals may be needed. However, in cases where only a portion of the coding sequence is inserted, exogenous translational control signals, including, perhaps, the ATG initiation codon, must be provided. Furthermore, the initiation codon must be in 20 phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see Bittner et al., *Methods in Enzymol.* 153:516-544, 25 1987).

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (for example, glycosylation) and processing (for example, cleavage) of protein products may be important for the 30 function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the 35 primary transcript, glycosylation, and phosphorylation of the gene product may be

used. The mammalian cell types listed above are among those that could serve as suitable host cells.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the MASP-2 sequences described above may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (for example, promoter, enhancer sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method can advantageously be used to engineer cell lines which express MASP-2. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that affect the endogenous activity of the gene product and for production of MASP-2 for therapeutic uses. These methods may also be used to modify cells that are introduced into a host organism either for experimental or therapeutic purposes. The introduced cells may be transient or permanent within the host organism.

A number of selection systems can be used. For example, the herpes simplex virus thymidine kinase (Wigler, et al., *Cell* 11:223, 1977), hypoxanthine-guanine phosphoribosyltransferase (Szybalska and Szybalski, *Proc. Natl. Acad. Sci. USA* 48:2026, 1962), and adenine phosphoribosyltransferase (Lowy, et al., *Cell* 22:817, 1980) genes can be employed in tk<sup>r</sup>, hgprt<sup>r</sup> or aprt<sup>r</sup> cells, respectively. Also, anti-metabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., *Proc. Natl. Acad. Sci. USA* 77:3567, 1980; O'Hare et al., *Proc. Natl. Acad. Sci. USA* 78:1527, 1981); gpt, which confers resistance to mycophenolic acid (Mulligan and Berg, *Proc. Natl. Acad. Sci. USA* 78:2072, 1981); neo, which confers resistance to the aminoglycoside G-418 (Colberre-Garapin et al., *J. Mol. Biol.* 150:1, 1981); and hygromycin (Santerre et al., *Gene* 30:147, 1984).

Alternatively, any fusion protein may be readily purified by utilizing an antibody specific for the fusion protein being expressed. For example, a system described by Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (*Proc. Natl. Acad. Sci. USA* 88: 8972-8976,

1991). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the gene's open reading frame is translationally fused to an amino-terminal tag consisting of six histidine residues. Extracts from cells infected with recombinant vaccinia virus are loaded onto  $\text{Ni}^{2+}$ -nitriloacetic acid-agarose columns and histidine-tagged proteins are selectively eluted with imidazole-containing buffers.

#### *MASP-2 polypeptides*

The MASP-2 polypeptides according to the present invention are polypeptides comprising amino acid sequences derived from SEQ ID NO. 2. Furthermore, MASP-2 polypeptides described herein are those encoded by any of the nucleic acid molecules described above and include MASP-2 fragments, mutants, truncated forms, and fusion proteins. These polypeptides can be prepared for a variety of uses, including but not limited to the generation of antibodies, as reagents in diagnostic assays, for the identification of other cellular gene products or compounds that can modulate the MBlectin response, and as pharmaceutical reagents useful for the treatment of inflammation and certain disorders (described below) that are associated with activity of the MBlectin pathway. Preferred polypeptides are substantially pure MASP-2 polypeptides, including those that correspond to the polypeptide with an intact signal sequence (extending from amino acids 1-15 of SEQ ID NO:2), the mature form of the polypeptide (extending from amino acids 16-686 of SEQ ID NO:2) of the human MASP-2 polypeptide as well as polypeptides representing a part of the MASP-2 polypeptide. Especially preferred are polypeptides that are soluble under normal physiological conditions.

In one embodiment the invention also encompasses polypeptides that are functionally equivalent to MASP-2. Functional equivalents may comprise only a fragment of the MASP-2 amino acid sequence as outlined in SEQ ID. 2. In preferred embodiments the MASP-2 polypeptides are selected from the group consisting of:

- i) Polypeptides comprising the sequence identified as SEQ ID NO 1 or a functional equivalent thereof; and
- ii) Polypeptides comprising the sequence identified as SEQ ID NO 1 having a molecular mass of 20 kD or a functional equivalent thereof; and
- iii) Polypeptide comprises amino acid 30 to 444 of SEQ ID NO. 2 or a functional equivalent thereof; and

- iv) Polypeptide comprises amino acid 30 to 444 of SEQ ID NO. having a molecular mass of 52 kD or a functional equivalent thereof; and
- v) Polypeptide comprising amino acid 138 to 296 of SEQ ID NO. 2 or a functional equivalent thereof; and
- 5 vi) Polypeptides comprising an amino acid sequence derived from SEQ ID NO 2 having serine protease activity or a functional equivalent thereof; and
- vii) Polypeptides comprising an amino acid sequence derived from SEQ ID NO 2 capable of MASP-2 activity in an in vitro assay for MBL complement pathway function; and
- 10 viii) Polypeptides comprising amino acid 15 to 671 of SEQ ID NO 3 or a functional equivalent thereof; and
- ix) Polypeptides comprising amino acid 16 to 296 of SEQ ID NO. 2 or a functional equivalent thereof; and
- 15 x) Polypeptides comprising amino acid 30 to 296 of SEQ ID NO. 2 or a functional equivalent thereof.

These polypeptides are equivalent to MASP-2 in that they are capable of carrying out one or more of the functions of MASP-2 in a biological system. Preferred MASP-2 polypeptides have 20%, 40%, 50%, 75%, 80%, or even 90% of the activity of the full-length, mature human form of MASP-2 described herein. Such comparisons are generally based on an assay of biological activity in which equal concentrations of the polypeptides are used and compared. The comparison can also be based on the amount of the polypeptide required to reach 50% of the maximal activity obtainable.

25 Functionally equivalent proteins can be those, for example, that contain additional, deleted or substituted amino acid residues. Substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. Amino acids that are typically considered to provide a conservative substitution for one another are specified in the summary of the invention. D-amino acids may be introduced in order to modify the half-life of the polypeptide.

30 Polypeptides that are functionally equivalent to MASP-2 (SEQ ID NO:2) can be made using random mutagenesis techniques well known to those skilled in the art (and the resulting mutant MASP-2 proteins can be tested for activity). It is more likely, however, that such polypeptides will be generated by site-directed mutagenesis

35

(again using techniques well known to those skilled in the art). These polypeptides may have an increased function, *i.e.*, a greater ability to activate the MBlectin pathway. Such polypeptides can be used to enhance the activity of MBlectin pathway immune function.

5           To design functionally equivalent polypeptides, it is useful to distinguish between conserved positions and variable positions. This can be done by aligning the sequence of MASP-2 cDNAs that were obtained from various organisms. Skilled artisans will recognize that conserved amino acid residues are more likely to be necessary for preservation of function. Thus, it is preferable that conserved residues  
10           are not altered.

          Mutations within the MASP-2 coding sequence can be made to generate MASP-2 peptides that are better suited for expression in a selected host cell. Introduction of a glycosylation sequence can also be used to generate a MASP-2 polypeptide with altered biological characteristics.

15           The invention also features methods for assay of polymorphisms within the polypeptide sequence comprising MASP-2 or its precursor. This may be accomplished by a number of techniques. For example, the purified polypeptide is subjected to tryptic digestion and the resulting fragments analyzed by either one- or two dimensional electrophoresis. The results from analysis of a sample polypeptide are compared to the  
20           results using a known sequence. Also the analysis may encompass separation of a biological sample (e.g., serum or other body fluids) by either one- or two-dimensional electrophoresis followed by transfer of the separated proteins onto a membrane (western blot). The membrane is then reacted with antibodies against MASP-2, followed by a secondary labelled antibody. The staining pattern is compared with that  
25           obtained using a sample with a known sequence or modification.

          The polypeptides of the invention can be expressed fused to another polypeptide, for example, a marker polypeptide or fusion partner. For example, the polypeptide can be fused to a hexa-histidine tag to facilitate purification of bacterially expressed protein or a hemagglutinin tag to facilitate purification of protein expressed  
30           in eukaryotic cells. The MASP-2 polypeptide of the invention, or a portion thereof, can also be altered so that it has a longer circulating half-life by fusion to an immunoglobulin Fc domain (Capon et al., Nature 337:525-531, 1989). Similarly, a dimeric form of the MASP-2 polypeptide can be produced, which has increased stability *in vivo*.



The polypeptides of the invention can be chemically synthesized (for example, see Creighton, "Proteins: Structures and Molecular Principles," W.H. Freeman & Co., NY, 1983), or, perhaps more advantageously, produced by recombinant DNA technology as described herein. For additional guidance, skilled artisans may consult Ausubel et al. (*supra*), Sambrook et al. ("Molecular Cloning, A Laboratory Manual," Cold Spring Harbor Press, Cold Spring Harbor, NY, 1989), and, particularly for examples of chemical synthesis Gait, M.J. Ed. ("Oligonucleotide Synthesis," IRL Press, Oxford, 1984).

The invention also features polypeptides that may be capable of competitively inhibiting MASP-2 activity. In one embodiment such polypeptides may be selected from the group consisting of:

- i) Polypeptides comprising a fragment of the polypeptide of SEQ ID NO: 2, said polypeptide being a competitive inhibitor of complexing of MBL/MASP-2 or a functional equivalent thereof; and
- ii) Polypeptides comprising the sequence identified as SEQ ID NO: 3 or a functional equivalent thereof, wherein one or more of the amino acid residues at position 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19 has been substituted with another amino acid residue; and
- iii) Polypeptides comprising the sequence identified as SEQ ID NO: 3 or a functional equivalent thereof, wherein at least two of the amino acid residues at position 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19 has been substituted with another amino acid residue; and
- iv) Polypeptides comprising the sequence identified as SEQ ID NO: 3 or a functional equivalent thereof, wherein the arg at position 14 has been substituted for another amino acid; and
- v) Polypeptides comprising the sequence identified as SEQ ID NO: 3 or a functional equivalent thereof, wherein the arg at position 14 has been substituted for an amino acid selected from the group consisting of small uncharged amino acids; and
- vi) Polypeptides comprising the sequence identified as SEQ ID NO: 3 or a functional equivalent thereof, wherein the arg at position 14 has been substituted for an amino acid selected from the group consisting of gly and ala; and

- vii) Polypeptides comprising fragments of mannan-binding lectin (MBL) that can associate with MASP-2 or functional homologues thereof.
- viii) Antibodies that selectively binds MASP-2

5

The invention also features polypeptides that interact with MASP-2 (and the genes that encode them) and thereby alter the function of MASP-2 interacting polypeptides can be identified using methods known to those skilled in the art. One suitable method is the "two-hybrid system," which detects protein interactions *in vivo* (Chien et al., *Proc. Natl. Acad. Sci. USA*, 88:9578, 1991). A kit for practicing this method is available from Clontech (Palo Alto, CA).

10

#### *Anti-MASP-2 antibodies*

15

Human MASP-2 polypeptides (or immunogenic fragments or analogs) can be used to raise antibodies useful in the invention; such polypeptides can be produced by recombinant techniques or synthesized (see, for example, "Solid Phase Peptide Synthesis," *supra*; Ausubel et al., *supra*). In general, the peptides can be coupled to a carrier protein, such as KLH, as described in Ausubel et al., *supra*, mixed with an adjuvant, and injected into a host mammal. Also the carrier could be PPD. Antibodies can be purified by peptide antigen affinity chromatography.

20

25

In particular, various host animals can be immunized by injection with a MASP-2 protein or polypeptide. Host animals include rabbits, mice, guinea pigs, rats, and chickens. Various adjuvants that can be used to increase the immunological response depend on the host species and include Freund's adjuvant (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol. Potentially useful human adjuvants include BCG (bacille Calmette-Guerin) and *Corynebacterium parvum*. Polyclonal antibodies are heterogeneous populations of antibody molecules that are contained in the sera of the immunized animals.

30

Antibodies within the invention therefore include polyclonal antibodies and, in addition, monoclonal antibodies, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab')<sub>2</sub> fragments, and molecules produced using a Fab expression library, and antibodies or fragments produced by phage display techniques.

35

Monoclonal antibodies, which are homogeneous populations of antibodies to a particular antigen, can be prepared using the MASP-2 proteins described above

and standard hybridoma technology (see, for example, Kohler et al., *Nature* 256:495, 1975; Kohler et al., *Eur. J. Immunol.* 6:511, 1976; Kohler et al., *Eur. J. Immunol.* 6:292, 1976; Hammerling et al., "Monoclonal Antibodies and T Cell Hybridomas," Elsevier, NY, 1981; Ausubel et al., *supra*).

5           In particular, monoclonal antibodies can be obtained by any technique that provides for the production of antibody molecules by continuous cell lines in culture such as described in Kohler et al., *Nature* 256:495, 1975, and U.S. Patent No. 4,376,110; the human B-cell hybridoma technique (Kosbor et al., *Immunology Today* 4:72, 1983; Cole et al., *Proc. Natl. Acad. Sci. USA* 80:2026, 1983), and the EBV-hybridoma technique (Cole et al., "Monoclonal Antibodies and Cancer Therapy," Alan R. Liss, Inc., pp. 77-96, 1983). Such antibodies can be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof. (In the case of chickens, the immunoglobulin class can also be IgY.) The hybridoma producing the mAb of this invention may be cultivated *in vitro* or *in vivo*. The ability to produce high titers of  
10 mAbs *in vivo* makes this the presently preferred method of production, but in some cases, *in vitro* production will be preferred to avoid introducing cancer cells into live animals, for example, in cases where the presence of normal immunoglobulins coming from the acitis fluids are unwanted, or in cases involving ethical considerations.

15           Once produced, polyclonal, monoclonal, or phage-derived antibodies are tested for specific MASP-2 recognition by Western blot or immunoprecipitation analysis by standard methods, e.g., as described in Ausubel et al., *supra*. Antibodies that specifically recognize and bind to MASP-2 are useful in the invention. For example, such antibodies can be used in an immunoassay to monitor the level of MASP-2 produced by an animal (for example, to determine the amount or subcellular location of MASP-2). Also, the antibodies may be used as MASP-2 inhibitors as discussed below.  
20

25           Preferably, antibodies of the invention are produced using fragments of the MASP-2 protein which lie outside highly conserved regions and appear likely to be antigenic, by criteria such as high frequency of charged residues. In one specific example, such fragments are generated by standard techniques of PCR, and are then cloned into the pGEX expression vector (Ausubel et al., *supra*). Fusion proteins are expressed in *E. coli* and purified using a glutathione agarose affinity matrix as described in Ausubel, et al., *supra*.  
30

35           In some cases it may be desirable to minimize the potential problems of low affinity or specificity of antisera. In such circumstances, two or three fusions can be generated for each protein, and each fusion can be injected into at least two rabbits.

Antisera can be raised by injections in a series, preferably including at least three booster injections.

Antisera is also checked for its ability to immunoprecipitate recombinant MASP-2 proteins or control proteins, such as glucocorticoid receptor, CAT, or luciferase.

The antibodies can be used, for example, in the detection of the MASP-2 in a biological sample as part of a diagnostic assay. Antibodies also can be used in a screening assay to measure the effect of a candidate compound on expression or localization of MASP-2. Additionally, such antibodies can be used in conjunction with the gene therapy techniques described to, for example, evaluate the normal and/or engineered MASP-2-expressing cells prior to their introduction into the patient. Such antibodies additionally can be used in a method for inhibiting abnormal MASP-2 activity.

In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al., *Proc. Natl. Acad. Sci. USA*, 81:6851, 1984; Neuberger et al., *Nature*, 312:604, 1984; Takeda et al., *Nature*, 314:452, 1984) by splicing the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region.

Alternatively, techniques described for the production of single chain antibodies (U.S. Patent Nos. 4,946,778, 4,946,778, and 4,704,692) can be adapted to produce single chain antibodies against a MASP-2 protein or polypeptide. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide.

Antibody fragments that recognize and bind to specific epitopes can be generated by known techniques. For example, such fragments include but are not limited to F(ab')<sub>2</sub> fragments that can be produced by pepsin digestion of the antibody molecule, and Fab fragments that can be generated by reducing the disulfide bridges of F(ab')<sub>2</sub> fragments. Alternatively, Fab expression libraries can be constructed (Huse et al., *Science*, 246:1275, 1989) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.

Antibodies to MASP-2 can, in turn, be used to generate anti-idiotypic antibodies that resemble a portion of MASP-2 using techniques well known to those

skilled in the art (see, e.g., Greenspan et al., *FASEB J.* 7:437, 1993; Nissinoff, *J. Immunol.* 147:2429, 1991). For example, antibodies that bind to MASP-2 and competitively inhibit the binding of a ligand of MASP-2 can be used to generate anti-idiotypes that resemble a ligand binding domain of MASP-2 and, therefore, bind and neutralize a ligand of MASP-2 such as MBL. Such neutralizing anti-idiotypic antibodies or Fab fragments of such anti-idiotypic antibodies can be used in therapeutic regimens.

Antibodies can be humanized by methods known in the art. For example, monoclonal antibodies with a desired binding specificity can be commercially humanized (Scotgene, Scotland; Oxford Molecular, Palo Alto, CA). Fully human antibodies, such as those expressed in transgenic animals are also features of the invention (Green et al., *Nature Genetics* 7:13-21, 1994; see also U.S. Patents 5,545,806 and 5,569,825, both of which are hereby incorporated by reference).

The methods described herein in which anti-MASP-2 antibodies are employed may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one specific MASP-2 nucleotide sequence or antibody reagent described herein, which may be conveniently used, for example, in clinical settings, to diagnose patients exhibiting symptoms of the disorders described below.

#### *Quantitative assays of MASP-2*

As an example only, quantitative assays may be devised for the estimation of MASP-2 concentrations in body fluids or organ (biopsy) extracts. Such assays may be fluid phase or solid phase. Examples are competitive and non-competitive ELISAs. As an example of the latter, microtiter wells are coated with anti-MASP-2 antibody, incubated with samples, and the presence of MASP-2 visualized with enzyme-labelled antibody followed by substrate that deposits a colored compound. Alternatively, a label such as europium may be used and the detection made by use of time resolved fluorometry.

Assays of the functional activity of MASP-2, either alone or as part of the MBL/MASP complex may be performed by several methods. As an example of a test for MBL/ MASP-2 complex, the test sample is applied onto mannan-coated micro wells and C4 is added to estimate the C4-cleaving activity, or C3 is added to estimate the C3 cleaving activity of the generated C3 convertase. Assay of MASP-2 not occurring as part of the MBL/MASP complex is carried out similarly, but MBL is added either to the micro well or to the sample before adding this to the mannan-coated well. Before the addition of MBL the sample may be depleted of MBL and MBL/MASP-1 and

MBL/MASP-2 complexes by treatment with solid phase mannan, e.g. attached to beads, or by solid phase anti-MBL antibodies, or by treatment with a suitable concentration of a precipitating agent, e.g., PEG, which precipitates the complex but leaves MASP-2 in the supernatant. The assay is carried out at conditions which minimize or eliminate interference from the classical complement activation pathway and the alternative complement activation pathway.

Assays estimating the activity of MASP-2 or MASP-2 may be used for diagnostic and treatment purposes in samples from individuals, notably those suffering from infectious or inflammatory diseases.

#### *MASP-2 for therapy*

Therapeutic use of components specified in the claims may be applied in situations where a constitutional or temporary deficiency in MASP-2 renders the individual susceptible to one or more infections, or situations where the individual cannot neutralize an established infection. In particular, the present invention relates to uses of MASP-2 for the preparation of a medicament for the treatment of infections. Even though preferably, MASP-2 deficient individuals may be treated with MASP-2, also individuals with normal MASP-2 activity in serum may be treated.

In a further embodiment of the present invention MASP-2 may be used for preparation of a medicament for the treatment of infections in an individual with low MBL serum levels. In such an embodiment the pharmaceutical composition preferably furthermore comprises at least one mannan-binding lectin (MBL) subunit, or at least one mannan-binding lectin (MBL) oligomer comprising the at least one mannan-binding lectin (MBL) subunit. Alternatively, MASP-2 and MBL may be administrated as a kit-of-parts.

Preferably, MBL oligomers according to the present invention is selected from the group of oligomers consisting of tetramers, pentamers and/or hexamers of MBL. MBL may be recombinantly produced or purified naturally occurring MBL. For example MBL may be any of the MBL species disclosed in patent applications PCT/DK00/00246 or PCT/DK00/00247, which are hereby incorporated by reference.

Low MBL serum levels according to the present invention are preferably MBL serum levels below 500 ng/ml, more preferably, MBL serum levels below 100 ng/ml, even more preferably, MBL serum level below 50 ng/ml.

5 Also, MASP-2 may be administrated to individuals receiving MBL treatment independent of the serum MBL level in order to secure sufficient amount of MASP-2 available for the administrated MBL.

10 MASP-2 or MBL/MASP complexes can be administered, preferably by intravenous infusions, in order to improve the individual's immune defense.

We believe MASP-2 is required for the powerful antimicrobial activity of the MBL/MASP complex, and deficiency in MASP-2, either genetically determined or acquired, will therefore compromise an individual's resistance to infections and ability to combat established infections. Reconstitution with natural or recombinant MASP-2 is  
15 a useful treatment modality in such situations. Recombinant MASP-2 may be in the form of the whole molecule, parts of the molecule, or the whole or part thereof attached by any means to another structure in order to modulate the activity. The recombinant products may be identical in structure to the natural molecule or slightly modified to yield enhanced activity or decreased activity when such is desired.

20 Reconstitution therapy with MBL, either natural or recombinant, requires that the recipient has sufficient MASP-2 for the expression of MBL/MASP activity. Thus, MASP-2 must be included in the therapeutic preparation when the patient has insufficient MASP-2 activity.

25 MASP-2 is preferably administrated in a dosage, which results in a concentration of MASP-2 in serum of the individual to be treated of between 50 ng/ml to 1000 µg/ml, preferably, between 100 ng/ml to 800 µg/ml, more preferably, between 500 ng/ml to 500 µg/ml, even more preferably, between 750 ng/ml to 250 µg/ml, yet more preferably, between 1 µg/ml to 100 µg/ml, even more preferably, between 2 µg/ml to  
30 50 µg/ml, most preferably, between 2 µg/ml to 10 µg/ml.

The infection which may be treated with the pharmaceutical compositions according to the present invention may be infection by any infectious agent. For example the infection may be caused by a microbial species.

The microbial species may be a fungus or the microbial species may be a yeast or the microbial species may be a bacteria or the microbial species may be a parasite.

5 Bacterias according to the present invention may for example be selected from the group consisting of *Achromobacter xylosoxidans*, *Acinetobacter calcoaceticus*, preferably *A. anitratus*, *A. haemolyticus*, *A. alcaligenes*, and *A. lwoffii*, *Actinomyces israelii*, *Aeromonas hydrophilia*, *Alcaligenes* species, preferably *A. faecalis*, *A. odorans* and *A. denitrificans*, *Arizona hinshawii*, *Bacillus anthracis*, *Bacillus cereus*, *Bacteroides fragilis*, *Bacteroides melaninogenicus*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Borrelia recurrentis*, *Brucella* species, preferably *B. abortus*, *B. suis*, *B. melitensis* and *B. canis*, *Calymmatobacterium granulomatis*, *Campylobacter fetus* ssp. *intestinalis*, *Campylobacter fetus* ssp. *jejuni*, *Chlamydia* species, preferably *C. psittaci* and *C. trachomatis*, *Chromobacterium violaceum*, *Citrobacter* species, preferably *C. freundii* and *C. diversus*, *Clostridium botulinum*, *Clostridium perfringens*, *Clostridium difficile*, *Clostridium tetani*, *Corynebacterium diphtheriae*, *Corynebacterium*, preferably *C. ulcerans*, *C. haemolyticum* and *C. pseudotuberculosis*, *Coxiella burnetii*, *Edwardsiella tarda*, *Eikenella corrodens*, *Enterobacter*, preferably *E. cloacae*, *E. aerogenes*, *E. hafniae* (also named *Hafnia alvei*) and *E. agglomerans*, *Erysipelothrix rhusiopathiae*, *Escherichia coli*, *Flavobacterium meningosepticum*, *Francisella tularensis*, *Fusobacterium nucleatum*, *Gardnerella vaginalis*, *Haemophilus ducreyi*, *Haemophilus influenzae*, *Helicobacter* species, *Klebsiella* species, preferably *K. pneumoniae*, *K. ozaenae* og *K. rhinoscleromatis*, *Legionella* species, *Leptospira interrogans*, *Listeria monocytogenes*, *Moraxella* species, preferably *M. lacunata* and *M. osloensis*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma* species, preferably *M. pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia* species, preferably *N. asteroides* and *N. brasiliensis*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Peptococcus magnus*, *Plesiomonas shigelloides*, *Pneumococci*, *Proteus* species, preferably *P. mirabilis*, *P. vulgaris*, *P. rettgeri* and *P. morganii* (also named *Providencia rettgeri* and *Morganella morganii* respectively), *Providencia* species, preferably *P. alcalifaciens*, *P. stuartii* and *P. rettgeri* (also named *Proteus rettgeri*), *Pseudomonas aeruginosa*, *Pseudomonas mallei*, *Pseudomonas pseudomallei*, *Rickettsia*, *Rochalimaia henselae*, *Salmonella* species, preferably *S. enteridis*, *S. typhi* and *S. derby*, and most preferably *Salmonella* species of the type *Salmonella* DT104, *Serratia* species,



preferably *S. marcescens*, *Shigella dysenteriae*, *S. flexneri*, *S. boydii* and *S. sonnei*, *Spirillum minor*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus saprophyticus*, *Streptobacillus moniliformis*, *Streptococcus*, preferably *S. faecalis*, *S. faecium* and *S. durans*, *Streptococcus agalactiae*,  
5 *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema carateum*, *Treponema pallidum*, *Treponema pertenue*, preferably *T. pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Yersinia enterocolitica*, and *Yersinia pestis*.

10 Parasites according to the present invention may for example be selected from the group consisting of Malaria (*Plasmodium falciparum*, *P. vivax*, *P. malariae*), Schistosomes, Trypanosomes, Leishmania, Filarial nematodes, Trichomoniasis, Sarcosporidiasis, Taenia (*T. saginata*, *T. solium*), Leishmania, *Toxoplasma gondii*, Trichinellosis (*Trichinella spiralis*) or Coccidiosis (*Eimeria* species).

15 Fungi may for example be selected from the group consisting of *Cryptococcus neoformans*, *Candida albicans*, *Aspergillus fumigatus* and *Coccidioidomycosis*.

20 In one preferred embodiment the bacterial species may be resistant to at least one antibiotic medicament. For example the bacterial species may be multiresistant. In one example the bacterial species is pathogenic.

In another embodiment of the present invention the infection is a viral infection, that is infection by a virus.

25 Viruses according to the present invention may for example be selected from the group consisting of: Adeno-associated virus, Adenovirus, Avian Infectious bronchitis virus, Baculovirus, Chicken pox, Corona virus, Cytomegalovirus, Distemper, Enterovirus, Epstein Barr virus, Feline leukemia virus, Flavivirus, Foot and mouth disease virus, Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis E, Herpes species, Herpes simplex, Influenza virus, HIV-1, HIV-2, HTLV 1, Influenza A and B, Kunjin virus, Lassa fever virus, LCMV (lymphocytic choriomeningitis virus), lentivirus, Measles, Mumps virus, Morbillivirus, Myxovirus, Papilloma virus, Parovirus, Parainfluenza virus, Paramyxovirus, Parvovirus, Poko virus, Polio virus, Polyoma tumour virus, pseudorabies, Rabies virus, Reovirus, Respiratory syncytial virus, retrovirus, rhinovirus,  
30 Rinderpest, Rotavirus, Semliki forest virus, Sendai virus, Simian Virus 40, Sindbis

virus, SV5, Tick borne encephalitis virus, Togavirus (rubella, yellow fever, dengue fever), Vaccinia virus, Venezuelan equine encephalomyelitis and Vesicular stomatitis virus.

- 5 In one preferred embodiment the virus is a retrovirus, such as for example Human Immunodeficiency Virus.

*Assays for MASP-2*

- 10 Therapy with MASP-2 (or MASP-2 inhibitors) must usually be preceded by the estimation of MASP-2 in serum or plasma from the patient. Examples of such assays are described below.

*Assays for MASP-2 antigen.*

- 15 MASP-2 protein is conveniently estimated as antigen using one of the standard immunological procedures.

- As an example only, a quantitative TRIFMA (time resolved immunofluorometric assay) for MASP-2 was constructed by 1) coating microtitre wells with 1 µg anti-C'MASP-2 antibody; 2) blocking with Tween-20; 3) applying test samples, e.g. diluted plasma or serum samples; 4) applying Eu-labelled anti-N' MASP-2 antibody; 5) applying enhancement solution (Wallac Ltd); 6) reading the Eu on a time resolved fluorometer. (Estimation by ELISA may be carried out similarly, e.g. by using biotin-labelled anti-N'MASP-2 in step 4; alkaline phosphatase-labelled avidin in step 5; 6) apply substrate; and 7) read the colour intensity.) Between each step, the plate was incubated at room temperature and washed, except between step 6 and 7. A calibration curve may be constructed using dilutions of pooled normal plasma, arbitrarily said to contain 1 unit of MASP-2 per ml. The antibodies used in this first version of a MASP-2 assay were raised against synthetic peptides and reacted poorly with native MASP-2. The samples are thus pretreated with SDS on a boiling water bath for 5 min. and the SDS neutralized with non-ionic detergent (Triton X-100) before the assay. A further development of the assay employs antibodies reacting with native MASP-2, thus rendering the SDS treatment superfluous.

Assays may be similarly constructed using antibodies, polyclonal or monoclonal or recombinant antibodies, which reacts with MASP-2, natural or recombinant, or parts thereof.

Through the use of antibodies reacting selectively with intact MASP-2 or with activation products, or through combination of antibodies against various parts of the molecule, assays may be constructed for the estimation of the activation *in vivo* of the MBLectin pathway. These assays will be useful for the determination of inflammation caused by the activation of this pathway.

*Assays for MASP-2 activity of the MBL/MASP complex.*

MASP-2 may be estimated by its capacity to activate the complement system. When C4 is cleaved by MASP-2 an active thiol ester is exposed and C4 becomes covalently attached to nearby nucleophilic groups. A substantial part of the C4b will thus become attached to the coated plastic well and may be detected by anti-C4 antibody. Thus, assays of the functional activity of MASP-2 either alone or as part of the MBL/MASP complex may be performed by several methods. The activity of MBL/MASP-2 to cleave the C4 may be assayed by the following method for detecting MASP-2, said method comprising an assay for MASP-2 activity, comprising the steps of

- applying a sample comprising a predetermined amount of MBL to a solid phase obtaining bound MBL,
- applying a predetermined amount of MASP-2 to the bound MBL
- applying at least one complement factor to the complexes,
- detecting the amount of cleaved complement factors,
- correlating the amount of cleaved complement factors to the amount of MASP-2, and
- determining the activity of MASP-2.

or

- applying a sample comprising a predetermined amount of MBL/MASP-2 complexes to a solid phase obtaining bound complexes,

- applying at least one complement factor to the complexes,
- detecting the amount of cleaved complement factors,
- correlating the amount of cleaved complement factors to the amount of MASP-2, and
- determining the activity of MASP-2.

A quantitative TRIFMA for MASP-2 activity was constructed by 1) coating microtitre wells with 1 µg mannan in 100 µl buffer; 2) blocking with Tween-20; 3) applying test samples, e.g. diluted plasma or serum samples; 4) applying purified complement factor C4 at 5 µg/ml; 5) incubate for one hour at 37°C; 6) applying Eu-labelled anti-C4 antibody; 7) applying enhancement solution; and 8) reading the Eu by time resolved fluorometry. (Estimation by ELISA may be carried out similarly, e.g. by applying biotin-labelled anti-C4 in step 6; 7) apply alkaline phosphatase-labelled avidin; 8) apply substrate; and 9) read the colour intensity). Between each step the plate was incubated at room temperature and washed, except between step 7 and 8. A calibration curve can be constructed using dilutions of one selected normal plasma, arbitrarily said to contain 1 unit of MBL/MASP-2 activity per ml. The assay is carried out at conditions which preclude activation of C4 by the classical or alternative complement activation pathways. The activation of C4 was completely inhibited by the serine protease inhibitor benzamidine. Activation of the classical complement pathway is preferably inhibited to reduce the artefacts of the assay. It is preferred that the inhibition is conducted by carrying out the assay at high ionic strength, such as wherein the salt concentration is above 0.2 M, such as above 2.5 M, such as in the range of from 0.3 M to 10 M, such as from 0.5 M to 5 M, such as from 0.7 M to 2 M, such as from 0.9 M to 2 M, such as about 1.0 M. The salts used may be any one or more salts suitable for the assay, such as salts selected from NaCl, KCl, MgCl<sub>2</sub>, CaCl<sub>2</sub>, NaI, KCl, MgI<sub>2</sub>, CaI<sub>2</sub>, from NaBr, KBr, MgBr<sub>2</sub>, CaBr<sub>2</sub>, Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>, (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, and NH<sub>4</sub>HCO<sub>3</sub>. The inhibition of the classical pathway does preferably not interfere with the MBL/MASP complex but destroys the C1qrs complex

The inhibition of the alternative pathway may be carried out by diluting the sample at least 5 times, such as at least 10 times, such as at least 20 times or more, before conducting the assay.

5      *Assays for the estimation of free MASP-2 activity.*

10      The estimation of MASP-2 activity in samples from MBL-deficient individuals is carried out on wells coated with MASP-free MBL. The estimation of free MASP in samples from individuals with MBL is carried out by first removing MBL/MASP-1 and MBL/MASP-2 complexes by incubating with Sepharose-coupled mannan (300  $\mu$ l of 10 fold diluted plasma or serum is incubated with 10  $\mu$ l beads), and then analyzing the supernatant.

15      The assay carried out in the TRIFMA format proceeds as follows: 1) coating microtitre wells with 1  $\mu$ g mannan in 100  $\mu$ l buffer; 2) blocking with Tween-20; 3) incubate sample at a 1000 fold dilution in buffer with 100 ng of MASP-free MBL/ml, and applying 100  $\mu$ l of the mixture per well; 4) incubate over night at 4°C; 4) wash and applying purified complement factor C4 at 5  $\mu$ g/ml; 5) incubate for one hour at 37°C; 6) applying Eu-labelled anti-C4 antibody; 7) applying enhancement solution; and 8) reading the Eu by time resolved fluorometry. (Estimation by ELISA may be carried out similarly, e.g. by applying biotin-labelled anti-C4 in step 6; 7) apply alkaline phosphatase-labelled avidin; 8) apply substrate; and 9) read the colour intensity.)  
20      Between each step the plate was washed, except between step 7 and 8. A calibration curve may be constructed using dilutions of one selected MBL-deficient plasma, arbitrarily said to contain 1 unit of MASP-2 activity per ml. The assay is carried out at conditions which preclude activation of C4 by the classical or alternative complement activation pathways (see above).

25      *Inhibition of MASP-2 activity.*

30      Inhibitors of the biological activity of MASP-2 may be employed to control the complement activating activity and inflammatory activity of MASP-2. Such inhibitors may be substrate analogues representing target structures of C2 or C4. Inhibitors may be of peptide nature, modified peptides, or any organic molecule which inhibits the activity of MASP-2 competitively or non-competitively. The inhibitor may be modified to stay in circulation for short or longer time, and constructed to be given by injection or perorally. Inhibitors may be fragments of MASP-2, produced from natural or recombinant MASP-2, by chemical or enzymatic procedures. Inhibitors may be  
35      naturally occurring shorter forms of MASP-2. Inhibitors may be in soluble form or

coupled to a solid phase. A solid phase could be a compatible surface such as used in extracorporal blood or plasma flow devices.

Microbial carbohydrates or endogenous oligosaccharides may provoke undesirable activation of the MBL/MASP complex resulting in damaging inflammatory responses. This pathophysiological activity may be reduced though the administration of inhibitors of MASP-2 activity such as Pefabloc. Also other enzyme inhibitors (PMSF, benzamidine, etc.) have proved effective when assayed in the TRIFMA for MASP-2 activity. Obviously, when designing inhibitors for *in vivo* use toxicity is a major consideration, and highly specific inhibitors can be assumed to be less toxic than more broadly reactive inhibitors. Specific inhibitors may be generated through using peptides, peptide analogues or peptide derivatives representing the target structures on complement factor C4 or C2 molecules. Another type of inhibitors may be based on antibodies (or fragments of antibodies) against the active site of MASP-2 or other structures on MASP-2 thus inhibiting the activity of MASP-2. The antibodies against MASP-2 are preferably the antibodies discussed above. Inhibitors may also be directed towards inhibition of the activation of MASP-2, thought to be effected by MASP-1, i.e. the target structure for MASP-1 on MASP-2 would be a suitable inhibitor of this type. Another type of inhibitor would prevent the binding of MASP-2 to MBL and thereby the activation of MASP-2. The N-terminal 20 kDa fragment of MASP-2 may be a suitable inhibitor of this type. More specifically one can localize the precise part of the polypeptide chain, which mediates the binding of MASP-2 to MBL and use the synthetic peptide or analogous structures as inhibitor. Inhibitors may be substituted with D amino acids for L-amino acids.

Also, inhibitors could be RNA or single stranded DNA isolated by SELEX (systemic evolution of ligands by exponential enrichment) using MASP-2 or fragments thereof as selecting molecule. The leader sequence of MASP-2 is shown elsewhere in this application.

Furthermore, inhibitors of MASP-2 could be a serine protease inhibitor, such as approtinin.

MASP-2 activity may be controlled by the conversion of the pro-enzyme form of MASP-2 into activated MASP-2 through the action of MASP-1 or any other substance simulating the activity of MASP-1.

## EXAMPLES

### *Example 1: Identification of MASP-2*

Human plasma proteins and protein complexes, that bind to carbohydrates in a calcium-dependent manner (i.e. lectins and lectin-associated proteins), were purified by affinity chromatography on mannan- and N-acetylglucosamine-derivatized Sepharose beads. Pooled CPD-plasma (2.5 l), diluted with buffer containing EDTA and enzyme inhibitors were passed through Sepharose 2B CL and mannan-Sepharose. A thrombin inhibitor, PPACK (D-phenylalanyl-prolyl-arginyl-chloromethyl ketone) and  $\text{CaCl}_2$  were added. The pool was passed through Sepharose 2B-CL and mannan-Sepharose, and the proteins binding calcium-dependently to mannan-Sepharose were eluted with EDTA-containing buffer. The eluate was recalcified, passed through a GlcNAc-Sepharose column which was eluted as above to yield 20 ml "lectin preparation".

This protein preparation was analyzed by SDS-PAGE and blotting onto a PVDF-membrane. Development of the blot with chicken antibody raised against a bovine lectin preparation<sup>25</sup> revealed a protein with an  $M_r$  of 52 kDa as well as MBL at 32 kDa. The 52 kDa band was subjected to  $\text{NH}_2$ -terminal amino acid sequence analysis. The sequence showed similarity to that of the previously described MASP (MASP-1). Antibody raised against a synthetic peptide representing the 19  $\text{NH}_2$ -terminal amino acids (anti-N'MASP-2 antiserum) recognized the 52 kDa molecule as well as a molecule with a mobility corresponding to 20 kDa (Fig. 1, lane 1). Under non-reducing conditions a polypeptide of 76 kDa was detected using the anti-N'-MASP-2 antiserum (Fig. 1, lane 2), indicating the presence of intra-chain disulphide bonds. The 20 kDa polypeptide was found to have the same  $\text{NH}_2$ -terminal sequence as the 52 kDa polypeptide and is likely to represent a truncated form of the latter. The directly determined amino acid sequences ( $\text{NH}_2$ -terminal as well as those of internal peptides) are indicated in Fig. 6. Two dimensional SDS-PAGE with the first dimension under nonreducing conditions and the second dimension under reducing conditions showed the 52 kDa polypeptide to be part of a disulphide-linked protein with an  $M_r$  of 76 kDa. A polypeptide of 31 kDa (Fig. 1, lane 3), likely to represent the remaining part of the protein, was also recognized as part of the 76 kDa protein by an antiserum (anti-C'MASP-2) raised against synthetic peptides representing sequences in the  $\text{COOH}$ -terminal part of the protein (determined by cDNA sequencing techniques; see below).

The 76 kDa band seen with the anti-N'MASP-2 antibody under non-reducing conditions was also recognized by the anti-C'MASP-2 antibody (Fig. 1, lane 4).

Figure 1b depicts SDS-PAGE in two dimensions, the first dimension under non-reducing conditions. The lane was cut out, incubated in sample buffer containing dithiothreitol (DTT), placed on top of another SDS-PAGE gel, and after electrophoresis, the gel was blotted and the blot developed with anti-N'MASP-2 antibody. The positions of molecular weight markers are indicated.

*Example 2: Preparation of antibodies against mamman-binding lectin associated serine proteases*

Animals, primed with BCG (Bacillus Calmette Guérin vaccine) were immunized with synthetic peptides coupled to PPD (tuberculin purified protein derivative) according to C. Koch, The State Serum Institute, Copenhagen. Antibody designated anti-N'MASP-1, anti-C'MASP-1 and anti-N'MASP-2 were from rabbits immunized with peptides corresponding to the first 19 amino acid residues of MASP-1, the last 19 amino acid residues of MASP-1 and the first 19 amino acid residues of MASP-2, respectively. Chicken anti-C'MASP-2 antibody was from chickens immunized with a mixture of two peptides representing sequences in the C-terminal part of MASP-2 (residues 505 to 523 and 538 to 556). All peptides had an additional C-terminal cysteine for coupling. Antibody and normal chicken IgG was purified from yolk<sup>26</sup>. Monoclonal anti-MBL antibody, IgG<sub>1</sub>-kappa (clone 131-1) and control IgG<sub>1</sub>-kappa (clone MOPC 21) were purified by Protein A affinity chromatography. F(ab')<sub>2</sub> rabbit anti-human C4 and F(ab')<sub>2</sub> rabbit anti-human C1q were produced by pepsin digestion of rabbit anti-human C4 and rabbit anti-human C1q (DAKO, Glostrup, Denmark). For staining of Western blots antibodies were used at 1 µg/ml. Bound chicken antibody was visualized with rabbit anti-chicken IgG followed by peroxidase-labelled goat anti-rabbit IgG and development using the enhanced chemiluminescence technique. Bound mouse and rabbit antibodies were visualized with peroxidase-labelled rabbit anti-mouse IgG and peroxidase-labelled goat anti-rabbit IgG, respectively.

*Example 3: Amino acid sequencing of the 52 kDa and the 20 kDa polypeptides*

The lectin preparation was concentrated, subjected to SDS-PAGE, and transferred to a PVDF membrane. Two strips were developed with anti-bovine lectin



antibody<sup>25</sup>. The rest of the blot was stained with Coomassie Brilliant Blue. The band corresponding to the immuno-stained 52 kDa band, judged to represent about 5% of the total Coomassie-stained proteins, was cut out and subjected to sequencing on an Applied Biosystems protein sequencer. After production of anti-N'MASP-2 antibody, a similar Western blot was performed using the anti-N-MASP-2 antibody. The NH<sub>2</sub>-termini of the proteins in the 52 kDa and the 20 kDa bands visualized with this antibody were sequenced. Peptides were prepared by trypsin digestion of the proteins in the two bands from another blot, fractionated by reverse phase chromatography and the peptides in the major peaks were subjected to sequencing.

#### *Example 4: Cloning and sequencing of MASP-2*

The liver is the primary site of synthesis of C1r, C1s, and MASP-1. Thus, RNA from liver was used as template for RT-PCR with primers deduced from the obtained peptide sequences. First strand synthesis of cDNA was carried out with 1.3 µg human liver RNA using a First-Strand cDNA Synthesis Kit (Pharmacia). PCR was performed on this cDNA using degenerate sense and antisense primers derived from the amino acid sequences EYANDQER and KPFTGFEA, respectively. The PCR program consisted of 1 cycle with annealing at 50°C; 1 cycle with annealing at 55°C, and 33 cycles with annealing at 60°C. The resulting 300 bp PCR product was cloned into the *E. coli* plasmid pCRII using the TA-cloning kit (Invitrogen) and the nucleotide sequence of the insert was determined.

The nucleotide sequence of the resulting 300 bp RT-PCR product contained an open reading frame (ORF) with a deduced amino acid sequence confirming the sequences of the peptides from which the primers were derived as well as that of another of the sequenced peptides. The insert of this plasmid was radioactively labelled and used as a probe for screening a total of  $8 \times 10^5$  clones in a commercial human liver library (Stratagene). Sixteen clones hybridized and the 4 longest (phl-1,2,3 and 4) were completely sequenced. Sequence analysis revealed that all four clones represent reverse transcripts of the same novel human mRNA species. The longest clone, phl-4, comprises 2475 bp starting with a 5' untranslated region of 36 bp followed by an ORF of 2061 bp and a 3' untranslated region of 378 bp ending with a poly-A tail. The nucleotide sequence of phl-4 is shown in Fig. 6 together with the translated amino acid sequence. The sequences are deposited at the EMBL nucleotide sequence data base (accession no. Y09926). While the sequence of phl-1

and -2 were in total agreement with phi-4, the nucleotide sequence of phi-3 differs from phi-4 at two positions, a transversion at nucleotide position 1147 (G to T) and a transition at position 1515 (C to T). The first change leads to the replacement of Asp 356 with Tyr. Because all clones were isolated from a liver library transcribed from RNA isolated from a single donor, the observed difference may represent a polymorphism in the MASP-2 gene, or is due to an error created during construction of the library.

The amino acid sequences of the NH<sub>2</sub>-terminus as well as all sequenced peptides were identified in the sequence deduced from clone phi-4. The ORF encodes a polypeptide chain of 686 amino acids including a signal peptide of 15 residues. Omitting the signal peptide, the calculated M<sub>r</sub> is 74,153, in agreement with the 76 kDa observed on SDS-PAGE (Fig. 1), the isoelectric point is 5.43 and the molar extinction coefficient is 113,640 (i.e. OD<sub>280nm</sub> = 1.54 at 1 mg/ml). In contrast to MASP-1 the sequence contains no sites for N-linked glycosylation. The three amino acid residues which are essential for the active centre in serine proteases (His 468, Asp 517, and Ser 618) are present.

*Example 5: Comparison of MASP-2 to MASP-1, C1r and C1s.*

The amino acid sequence deduced from the cDNA sequences is homologous to those of MASP-1, C1r and C1s (Fig. 2). Notably, the domain organization is common to these four proteins, featuring one C1r/C1s-like domain, one epidermal growth factor-like (EGF-like) domain, followed by a second C1r/C1s-like domain, two complement control protein (CCP) domains, and a serine protease domain. The key residues involved in the calcium-binding motif in the epidermal growth factor-like domains are present in the obtained sequence, as well as in MASP-1, C1r and C1s. In addition, the substrate specificity related residue, 6 residues before the active site serine, is aspartic acid in all four proteins. MASP-1, C1r, and C1s are all activated by cleavage of the peptide bond between the residues Arg and Ile located between the second CCP domain and the serine protease domain. The resulting polypeptide chains (the largest referred to as the "heavy chain" and the smallest as "light chain") are held together by a disulphide bond. By analogy, our results indicate that the 52 kDa polypeptide, recognized by antibody against the N-terminal of MASP-2 after SDS-PAGE under reducing conditions, is the heavy chain of MASP-2, whereas the 31 kDa polypeptide, recognized by antibody against the C-terminal of MASP-2, is

the light chain. As seen in Fig. 2, Arg and Ile are present in MASP-2 at the expected positions between the second CCP domain and the protease domain.

Identities and similarities between the four proteins were studied based on the alignment in Fig. 2. A bias of 6 was added to each term of the mutation data matrix (250PAMS) and a break penalty of 6 was used. Identical residues in all four species are indicated by asterisks. The beginning of the C1r/C1s-like domains, the EGF-like domain and the CCP domains are indicated above the sequences. The aligned cysteines are shaded. The potential cleavage site between Arg and Ile residues, which generates heavy and light chains, is identical to the site where the serine protease domain starts. The three amino acid residues, which are essential for the active centre in serine proteases (His 468, Asp 517 and Ser 618), are indicated ( $\diamond$ ). The cysteines in the histidine-loop of MASP-1 are marked ( $\nabla$ ). The sequences obtained by amino acid sequencing of peptides are underlined. The identities between the proteins (Fig. 2) are all in the range of 39% to 45% and gives no clue to functional relatedness. The similarity, i.e. taking into account residues of similar nature as well as identical residues, between the proteins (Fig. 3b) are between 39 and 52% with the least similarity being between MASP-1 and C1s (39%) and the highest similarity between MASP-1 and C1r (52%) and between MASP-1 and MASP-2 (52%). MASP-2 shows similarity with C1r (46%) and C1s (47%). Whereas the relative identities gives no clue as to functional relatedness the similarity score between C1s and MASP-2 is significantly higher than between C1s and MASP-1 while MASP-1 is more similar to C1r than to C1s, suggesting that MASP-2, like C1s, could be a C2 and C4 cleaving enzyme. Several features of the sequences suggest that MASP-2, C1r and C1s have evolved by gene duplication and divergence from a MASP-1 ancestor. Only the MASP-1 sequence contains the histidine loop, characteristic of trypsin-like serine proteases<sup>27</sup>. The active site serine is encoded by a TCN codon (N is A, T, G or C) in MASP-1 as in most serine proteases, whereas in MASP-2, C1r and C1s it is encoded by an AGY codon (where Y is T or C). In most serine proteases, including MASP-1, a proline residue is found at the third position downstream from the active site serine, whereas a different amino acid is found in MASP-2, C1s and C1r (alanine in MASP-2 and C1s, valine in C1r). Based on these analogies one may predict that the catalytic domain of MASP-2 is encoded by a single exon as in C1r and C1s, whereas most other serine proteases, including MASP-1<sup>28</sup>, have split exons.

*Example 6: MBL/MASP complexes.*

The lectin preparation described above was incubated in microtitre wells coated with monoclonal anti-MBL antibody, or, as a negative control, wells coated with non-specific monoclonal immunoglobulin of the same subclass. The proteins captured by the antibody were eluted and analyzed by SDS-PAGE/Western blotting. The results (Fig.3a) show that the anti-MBL antibody, in addition to binding MBL, captures both MASP-1 and MASP-2. Microtitre wells were coated with monoclonal anti-MBL or control monoclonal murine IgG1, incubated with either one of two different lectin preparations (a and b), and the bound proteins were eluted and analysed by SDS-PAGE under reducing conditions and Western blotting. Blot a was developed with anti-MBL antibody, blot b with anti-C'MASP-1 antibody and blot c with anti-N'MASP-2 antibody. Lane 1 represents unfractionated lectin preparation a. Lanes 3 and 4 represent eluates from wells coated with anti-MBL antibody and incubated with lectin preparation b and a, respectively, while lanes 2 and 5 represent eluates from wells coated with normal IgG and incubated with lectin preparation b and a, respectively.

Fractions from gel permeation chromatography (GPC) of the lectin preparation on Superose 6B CL were analyzed for MBL, MASP-1 and MASP-2 (Fig. 3a). The lectin preparation was subjected to GPC on a Superose 6 column in buffer containing calcium. MBL was eluted in a main peak at a volume ( $V_e$ ) corresponding to an  $M_r$  of 750 kDa, and a smaller peak at a position corresponding to 350 kDa. Panel A shows the results of analysis of the fractions by Western blotting using monoclonal anti-MBL antibody. The band at about 60 kDa is seen in all MBL preparations and is recognized by all the anti-MBL antibodies tested (monoclonal as well as polyclonal) and thus probably represents a non-reducible dimer of the 32 kDa polypeptide chain. Panel B shows the same analysis using anti-N'MASP-2 antibody (developing the upper band of 52 kDa) followed by anti-C'MASP-1 antibody (developing the lower band of 31 kDa). For purely technical reasons the 20 kDa truncated MASP-2 is not seen in this picture where the blot was partially stripped between the incubations with anti-MASP-2 and anti-MASP-1. The arrows on the chromatogram indicate the void volume (1) and the elution positions for the following marker proteins IgM (2), C1q (3), thyroglobulin (4), IgG (5) and serum albumin (6).

Masp-1 and MASP-2 co-elute largely with the high molecular weight MBL. Chromatography of the MBL preparation at pH 5 revealed that no MASP-1 or MASP-2 was associated with MBL. See, Tan et al. (1996, Biochem J. 319: 329-332).

*Example 7: Complement activation.*

The classical complement activation pathway, as well as the MBL-initiated pathway involves the generation of a C3 converting complex, C4b2b, through enzymatic activation of C4 and C2. In the C1 complex (C1q<sub>2</sub>s<sub>2</sub>) this specific protease activity is exhibited by C1s after activation of the enzyme by C1r. Upon activation of C4, a reactive thiol ester is exposed and C4b covalently binds to nearby amino or hydroxyl groups.

The C4 activating potentials of MASP-1 and MASP-2, and C1r and C1s, were compared. This was accomplished by separating a C1 preparation and an MBL/MASP preparation by SDS-PAGE followed by Western blotting. The blot was examined for C4 converting activity by incubation with human serum at 37°C, followed by detection of deposited C4b using anti-C4 antibodies.

C1 was purified by incubating IgG-coupled Sepharose beads with human serum at 4°C. The beads were washed and incubated at 37°C for 30 minutes for activation of C1r and C1s. The beads were suspended in non-reducing sample buffer and, without boiling, subjected to SDS-PAGE, followed by blotting in the absence of SDS. A similar blot was made of an MBL preparation produced in the absence of enzyme inhibitors (The State Serum Institute, Copenhagen). Strips of the blots were incubated for 30 minutes at 37°C with 1.1% (v/v) human MBL-deficient serum, depleted of C1q by fractionation on Biorex 70. The blots were developed with biotinylated F(ab')<sub>2</sub> anti-C4 antibody followed by peroxidase-labelled streptavidin and luminescence reagent. Parallel blots were treated with a serine protease inhibitor (aminoethylbenzenesulfonyl fluoride), which was also present during incubation with serum. Other strips were directly developed with antibodies.

The results in Fig. 4 show that C4 was deposited at a position corresponding to the MASP-2 band, whereas no C4 deposition was observed at positions corresponding to MASP-1. MASP-1 was present in the activated state as shown by SDS-PAGE under reducing conditions where it appears as two bands at about 30 kDa and 70 kDa, respectively (not shown). The observed C4 activation and deposition was inhibited by serine protease inhibitors (Fig. 4). It was also observed that no C4 activating activity could be detected when MBL/MASP was prepared in the presence of enzyme inhibitors added throughout the purification procedure. A preparation of C1 was analyzed similarly and C4 deposition, which could be inhibited

by enzyme inhibitors, was observed at a position corresponding to C1r and C1s, which are not separated by the technique employed.

Figure 4 is a representation of Western blots demonstrating the activation of C4 by C1s and MASP-2. Panel A shows a Western blot of C1 separated under non-reducing conditions, and without heating the sample before electrophoresis. Lane 1 was developed with anti-C1s antibody. Lane 2 was incubated with human serum followed by anti-C4 antibody. Lane 3 was as lane 2 except for the presence of serine protease inhibitors during the incubation with serum. Panel B shows a Western blot of an MBL preparation separated as in A. Lane 1 was developed with anti-N'MASP-1, lane 2 with anti-N'MASP-2. Lane 3 was incubated with human serum at 37°C followed by anti-C4. In lane 4 the blot was preincubated with serine protease inhibitors and the incubation with serum was also in the presence of inhibitors. MASP-1 shows a higher  $M_r$  than MASP-2 due to glycosylation<sup>17</sup> and a polypeptide chain 9 amino acids longer.

Our results emphasize the similarity between complement activation through the MBlectin pathway of the innate immune system and the classical pathway of complement activation (Fig. 5). Activation via the classical pathway is associated with the specific immune response found only in vertebrates, while the MBlectin pathway and the alternative pathway rely on innate recognition of foreign organisms and are thus likely to predate the evolution of the specific immune system. All pathways converge on the activation of the central component C3 into C3b, which binds covalently to the microbial surface and mediates the effector functions of complement.

In both the classical and MBlectin pathways, the initiating molecular complexes are composed of an oligomeric ligand-binding component (MBL or C1q, respectively) which, on reacting with ligands, activates the two associated serine proteases (MASP-1 and MASP-2 or C1r and C1s, respectively).

## References

- 1) Law, S.K.A. & Reid, K.B.M. *Complement*, 2. ed. (Ed. Male, D.) 1-88 (*In Focus*, IRL Press, Oxford, 1996).
- 2) Ikeda, K., Sannoh, T., Kawasaki, N., Kawasaki, T. & Yamashina, I. Serum lectin with known structure activates complement through the classical pathway. *J. Biol. Chem.* **262**, 7451-7454 (1987).

3) Kawasaki, T., Etoh, R. & Yamashina, I. Isolation and characterization of a mannan-binding protein from rabbit liver. *Biochem. Biophys. Res. Commun.* **81**, 1018-1024 (1978).

5

4) Matsushita, M. & Fujita, T. 4) Activation of the classical complement pathway by mannose-binding protein in association with a novel C1s-like serine protease *J. Exp. Med.* **176**, 1497-1502 (1992).

10

5) Ji, Y-H. *et al.* Activation of the C4 and C2 components of complement by a proteinase in serum bactericidal factor, Ra reactive factor *J. Immunol.* **150**, 571-578 (1993).

15

6) Turner, M.W. Mannose-binding lectin: the pluripotent molecule of the innate immune system. *Immunol. Today*, **17**, 532-540 (1996).

20

7) Kawasaki, N., Kawasaki, T. & Yamashina, I. A serum lectin (mannan-binding protein) has complement-dependent bactericidal activity. *J. Biochem.* **106**, 483-489 (1989).

25

9) Sumiya, M. *et al.* Molecular basis of opsonic defect in immunodeficient children. *Lancet* **337**, 1569-1570 (1991).

30

10) Lipscombe, R.J. *et al.* High frequencies in African and non-African populations of independent mutations in the mannose binding protein gene. *Hum. Mol. Genet.* **1**, 709-715 (1992).

11) Madsen H.O. *et al.* A new frequent allele is the missing link in the structural polymorphism of the human mannan-binding protein. *Immunogenetics* **40**, 37-44 (1994).

- 12) Super, M., Thiel, S., Lu, J., Levinsky, R.J. & Turner, M.W. Association of low levels of mannan-binding protein with a common defect of opsonisation. *Lancet* II, 1236-1239 (1989).
- 5 13) Garred, P., Madsen, H.O., Hofmann, B. & Svejgaard, A. Increased frequency of homozygosity of abnormal mannan-binding-protein alleles in patients with suspected immunodeficiency. *Lancet* 346, 941-943 (1995).
- 10 14) Summerfield, J.A. *et al.* Mannose binding protein gene mutations associated with unusual and severe infections in adults. *Lancet* 345, 886-889 (1995).
- 15 15) Nielsen, S.L., Andersen, P.L., Koch, C., Jensenius, J.C. & Thiel, S. The level of the serum opsonin, mannan-binding protein in HIV-1 antibody-positive patients. *Clin. Exp. Immunol.* 100, 219-222 (1995).
- 16 16) Garred, P., Madsen, H.O., Balslev, U., Hofmann, B., Pedersen, C., Gerstoft, J. and Svejgaard, A. Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. *Lancet* 349, 236-240 (1997).
- 20 17) Malhotra, R. Wormald, M.R., Rudd, P.M., Fischer, P.B., Dwek, R.A. and Sim, R.B. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. *Nature Med.* 1, 237-243 (1995).
- 25 18) Kilpatrick, D.C., Bevan, B.H. and Liston, W.A. Association between mannan-binding protein deficiency and recurrent miscarriage. *Mol. Hum. Reprod.* 1, 2501-2505 (1995).
- 30 19) Davies, E.J., Snowden, N., Hillarby, M.C., Carthy, D. Grennan, D.M., Thomson, W. and Ollier, W.E.R. Mannose-binding protein gene polymorphism in systemic lupus erythematosus. *Arthritis Rheum.* 38, 110-114 (1995).
- 35 20) Jensenius, J.C. Mannan-binding lectin (MBL): From investigations on fish and chickens to substitution therapy in an infant with severe infections. *Immunology*, 86, Suppl. 1, 100, abstract (1995).



- 21) Garred, P., Madsen, H.O., Kurtzhals, J.A., et al. Diallelic polymorphism may explain variations of blood concentrations of mannan-binding protein in Eskimos but not in black Africans. *Eur. J. Immunogenet.* **19**, 403-412 (1992).
- 5      22) Thiel, S., Jensen, T.V., Laursen, S.B., Willis, A. and Jensenius, J.C. Identification of a new mannan-binding protein associated serine protease (MASP-2). *Immunology* **86**, Suppl. 1, 101 (1995).
- 10      23) Thiel, S., Jensen, T.V., Laursen, S.B., Willis, A., Reid, K.B.M., Hansen, S. and Jensenius, J.C. Identification of a new mannan-binding lectin associated serine protease (MASP-2). *Mol. Immunol.*, **33**, Suppl. 1, 91 (1996).
- 15      24) Jensen, T.V., Stover, C., Poulsen, K., Laursen, S.B., Eggleston, P., Reid, K.B.M., Willis, A., Schwaebler, W., Lu, J., Holmskov, U., Jensenius, J.C. and Thiel, S. Cloning of cDNA encoding a human MASP-like protein (MASDP-2). *Mol. Immunol.*, **33**, Suppl. 1, 81 (1996).
- 20      25) Baatrup, G., Thiel, S., Isager, H., Svehag, S.E. & Jensenius, J.C. Demonstration in human plasma of a lectin activity analogous to that of bovine conglutinin. *Scand. J. Immunol.* **26**, 355-361 (1987).
- 25      26) Jensenius, J.C., Andersen, I., Hau, J., Crone, M. & Koch, C. Eggs: conveniently packaged antibodies. Methods for purification of yolk IgG. *J. Immunol. Methods.* **46**, 63-66 (1981).
- 30      27) Sato, T., Endo, Y., Matsushita, M. & Fujita, T. Molecular characterization of a novel serine protease involved in activation of the complement system by mannose-binding protein. *Int. Immunol.* **6**, 665-669 (1994).
- 28) Endo, Y., Sato, T., Matsushita, M. & Fujita, T. Exon structure of the gene encoding the human mannose-binding protein-associated serine protease light chain: comparison with complement C1r and C1s genes. *Int. Immunol.* **9**, 1355-1358 (1996).

- 29) Tan, S.M., Chung, M.C.M., Kon, O.L., Thiel, S. Lee, S.H. & Lu, J. Improvements on the purification of mannan-binding lectin and demonstration of its  $\text{Ca}^{2+}$ - independent association with a C1s-like serine protease. *Biochem. J.* **319**, 329-332 (1996).
- 5 30) Barton, G. J. Protein multiple sequence alignment and flexible pattern matching. *Methods Enzymol.* **183**, 403-428 (1990).
- 10 31) Takada, F., Takayama, Y., Hatsuse, H. & Kawakami, M. A new member of the C1s family of complement proteins found in a bactericidal factor, Ra-reactive factor, in human serum. *Biochem. Biophys. Res. Comm.* **196**, 1003-1009 (1993).
- 32) Journat, A. & Tosi, M. Cloning and sequencing of full-length cDNA encoding the precursor of human complement component C1r. *Biochem. J.* **240**, 783-787 (1986).
- 15 33) Lytus, S.P., Kurachi, K., Sakariassen, K.S. & Davie, E.W. Nucleotide sequence of cDNA coding for human complement C1r. *Biochemistry* **25**, 4855-4863 (1986).
- 20 34) Mackinnon, C.M., Carter, P.E., Smyth, S.J., Dunbar, B. & Fothergill, J.E. Molecular cloning of cDNA for human complement component C1s. The complete amino acid sequence. *Eur. J. Biochem.* **169**, 547-553 (1987).
- 25 35) Tosi, M., Duponchel, C., Meo, T. & Julier, C. Complete cDNA sequence of human complement C1s and close physical linkage of the homologous genes C1s and C1r. *Biochemistry* **26**, 8516-8524 (1987).

**Claims**

1. Use of a substantially pure polypeptide comprising amino acid sequences derived from mannan-binding lectin associated serine protease-2 (MASP-2) (SEQ ID. 2) or a functional homologue thereof for the production of a pharmaceutical composition.
2. The use according to claim 1, wherein the polypeptide comprises the sequence as identified SEQ ID NO. 3.
3. The use according to claim 1, wherein the polypeptide is capable of associating with mannan-binding lectin (MBL).
4. The use according to claim 1 or 2, wherein the polypeptide is conjugated to a label or a toxin.
5. The use according to any of the preceding claims, wherein the polypeptide comprises the sequence identified as SEQ ID NO 1, or a functional equivalent thereof.
6. The use according to any of the preceding claims, wherein the polypeptide has a molecular mass of 20 kD.
7. The use according to any of claims 1 to 4, wherein the polypeptide comprises amino acid 30 to 444 of SEQ ID NO. 2.
8. The use according to any of the preceding claims, wherein the polypeptide has a molecular mass of 52 kD.
9. The use according to any of claims 1 to 4, wherein the polypeptide comprises amino acid 138 to 296 of SEQ ID NO. 2.
10. The use according to any of the preceding claims, wherein the polypeptide has serine protease activity.

11. The use according to any of the preceding claims, wherein the polypeptide is capable of MASP-2 activity in an in vitro assay for MBL complement pathway function.
- 5 12. The use according to claim 10 or 11, wherein the polypeptide comprises amino acid 15 to 671 of SEQ ID NO 3.
13. The use according to claim 10 or 11, wherein the polypeptide comprises amino acid 16 to 296 of SEQ ID NO. 2.
- 10 14. The use according to claim 10 or 11, wherein the polypeptide comprises amino acid 30 to 296 of SEQ ID NO. 2
- 15 15. The use according to any of claims 1 to 4, wherein the polypeptide is capable of competitively inhibiting MASP-2 activity.
- 16 16. The use according to claim 15, wherein the polypeptide comprises a fragment of the polypeptide of SEQ ID NO: 2, said polypeptide being a competitive inhibitor of complexing of MBL/MASP-2.
- 20 17. The use according to claim 15 or 16, wherein the polypeptide comprises the sequence identified as SEQ ID NO: 3 or a functional equivalent thereof, wherein one or more of the amino acid residues at position 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19 has been substituted with another amino acid residue.
- 25 18. The use according to claim 17, wherein the at least two amino acid residues have been substituted.
- 30 19. The use according to claim 17, wherein the arg at position 14 of SEQ ID. NO 3 has been substituted for another amino acid.
- 35 20. The use according to claim 17, wherein the arg at position 14 of SEQ ID. NO 3 has been substituted for an amino acid selected from the group consisting of small uncharged amino acids.

21. The use according to claim 17, wherein the arg at position 14 of SEQ ID. NO 3 has been substituted for an amino acid selected from the group consisting of gly and ala.

5 22. The use according to any of the preceding claims, wherein the pharmaceutical composition is for the treatment of infections.

23. The use according to claim 22, wherein the infections is an infection caused by a microbial species.

10 24. The use according to claim 23, wherein the microbial species is a fungus.

25. The use according to claim 23, wherein the microbial species is a yeast.

15 26. The use according to claim 23, wherein the microbial species is a bacteria.

27. The use according to claim 26, wherein the bacterial species is resistant to at least one antibiotic medicament.

20 28. The use according to claim 26, wherein the bacterial species is multiresistent.

29. The use according to claim 26, wherein the bacterial species is pathogenic.

25 30. The use according to claim 22, wherein the infection is a viral infection.

31. The use according to claim 30, wherein the virus is a retrovirus.

32. The use according to claim 31, wherein the retrovirus is a Human Immunodeficiency Virus.

30 33. The use according to claim 1, wherein the pharmaceutical composition furthermore comprises at least one mannan-binding lectin (MBL) subunit, or at least one mannan-binding lectin (MBL) oligomer comprising the at least one mannan-binding lectin (MBL) subunit.

35

- 5 34. The use according to claim 1, further comprising the use of at least one mannan-binding lectin (MBL) subunit, or at least one mannan-binding lectin (MBL) oligomer comprising the at least one mannan-binding lectin (MBL) subunit for the manufacture of a medicament for obtaining a kit-of-parts.
35. The use according to any of claims 33 and 34, wherein said oligomer is preferably selected from the group of oligomers consisting of tetramers, pentamers and/or hexamers of MBL.
- 10 36. The use according to any of the claims 33 to 35, wherein the pharmaceutical composition is for the treatment of infections in an individual with MBL serum level below 500 ng/ml.
- 15 37. The use according to any of the claims 33 to 35, wherein the pharmaceutical composition is for the treatment of infections in an individual with MBL serum level below 100 ng/ml.
- 20 38. The use according to any of the claims 33 to 35, wherein the pharmaceutical composition is for the treatment of infections in an individual with MBL serum level below 50 ng/ml.
- 25 39. A polypeptide containing the sequence identified as SEQ ID NO. 1 or a functional homologue thereof.
40. The polypeptide according to claim 39, wherein the polypeptide has a molecular mass of 20 kD.
- 30 41. The polypeptide according to claim 39, wherein the polypeptide comprises amino acid 30 to 444 of SEQ. ID: NO. 2.
42. The polypeptide according to claim 39, wherein the polypeptide has a molecular mass of 52 kD
- 35 43. The polypeptide according to claim 39, wherein the polypeptide comprises amino acid 138 to 296 of SEQ ID NO.2.

44. The polypeptide of claim 39, said polypeptide having serine protease activity.

5 45. The polypeptide according to claim 39, wherein the polypeptide comprises amino acid 15 to 671 of SEQ ID NO 3.

46. The polypeptide according to claim 39, wherein the polypeptide comprises amino acid 16 to 296 of SEQ ID NO. 2.

10 47. The polypeptide according to claim 39, wherein the polypeptide comprises amino acid 30 to 296 of SEQ ID NO. 2

15 48. The polypeptide of claim 39, said polypeptide being capable of MASP-2 activity in an *in vitro* assay for MBLectin complement pathway function.

49. The polypeptide according to claim 39, said polypeptide being capable of competitively inhibiting MASP-2 serine protease activity.

20 50. The polypeptide according to claim 39, comprising the sequence as identified by SEQ ID NO. 3 or a functional homologue thereof, said polypeptide being a competitive inhibitor of complexing of MBL/MASP-2.

25 51. The polypeptide according to claim 39, comprising the sequence as identified by SEQ ID NO. 3 or a functional homologue thereof, wherein one or more of the amino acid residues at position 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or 19 has been substituted for another amino acid residue.

30 52. The polypeptide according to claim 51, wherein the at least two amino acid residues have been substituted.

53. The polypeptide according to claim 51, wherein the arg at position 14 of SEQ ID. NO 3 has been substituted for another amino acid.

54. The polypeptide according to claim 51, wherein the arg at position 14 of SEQ ID. NO 3 has been substituted for an amino acid selected from the group consisting of small uncharged amino acids.
- 5 55. The polypeptide according to claim 51, wherein the arg at position 14 of SEQ ID. NO 3 has been substituted for an amino acid selected from the group consisting of gly and ala.
- 10 56. The polypeptide according to any of claims 39 to 55, wherein said polypeptide is conjugated to a label or toxin.
- 15 57. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having a sequence that is at least 85% identical to the polypeptide sequence according to any of claims 39, 41, 43, 45, 46, 47 and 50 to 55.
58. A nucleic acid vector comprising the nucleic acid molecule of claim 57.
59. The vector of claim 58, wherein said vector is an expression vector.
- 20 60. The vector of claim 58, further comprising a regulatory element.
61. A use of a compound capable of competitively inhibiting activity of MASP-2 or a functional homologue thereof for the preparation of a medicament.
- 25 62. The use according to claim 61, wherein the compound is capable of competitively inhibiting activity of MASP-2.
63. The use according to claim 61, wherein the compound is a polypeptide according to any of claims 49 to 55.
- 30 64. The use according to claim 61, wherein the compound is a fragment of mannan-binding lectin (MBL) that is capable of associating with MASP-2.
- 35 65. The use according to claim 61, wherein the compound is an antibody produced by administering an MASP-2 polypeptide to an antibody producing animal.



66. The use according to claim 61, wherein the compound is an antibody that selectively binds to MASP-2.

5 67. The use according to any of claims 65 and 66, wherein the antibody is a monoclonal antibody.

68. The use according to any of claims 65 and 66, wherein the antibody is being coupled to a compound comprising a detectable marker.

10

69. A pharmaceutical composition comprising a substantially pure polypeptide comprising amino acid sequences derived from mannan-binding lectin associated serine protease-2 (MASP-2) (SEQ ID. 2) or a functional homologue thereof for the production of a pharmaceutical composition.

15

70. The pharmaceutical composition according to claim 69, wherein the polypeptide comprises the sequence as identified SEQ ID NO. 3.

20

71. The pharmaceutical composition according to claim 69, wherein the polypeptide is capable of associating with mannan-binding lectin (MBL).

72. The pharmaceutical composition according to claim 69, wherein the polypeptide is conjugated to a label or a toxin.

25

73. The pharmaceutical composition according to claim 69, comprising the polypeptide according to any of claims 39 to 55.

74. A method for detecting mannan-binding lectin associated serine protease-2 (MASP-2), said method comprising:

30

- (a) obtaining a biological sample;
- (b) contacting said biological sample with a MASP-2 polypeptide specific binding partner that specifically binds MASP-2; and
- (c) detecting said complexes, if any, as an indication of the presence of mannan-binding lectin associated serine protease-2 in said sample.

35

75. The method according to claim 74, in which the specific binding partner is an antibody.
- 5 76. A method for detecting MASP-2, said method comprising an assay for MASP-2 complement fixing activity.
77. The methods of claims 74 or 76 for quantitative assay of MASP-2 or MASP-2 activity in biological samples.
- 10 78. A method for detecting MASP-2 nucleic acid expression, comprising detecting RNA having a sequence encoding a MASP-2 polypeptide by mixing the sample with a nucleic acid probe that specifically hybridizes under stringent conditions to the nucleic acid of claim 57.
- 15 79. A method for treating patients deficient in MASP-2 by administering to the patient the peptide according to any of claims 39 to 42 and 45 to 47.
80. A method for treating patients deficient in MASP-2 by administering to the patient nucleic acid according to claim 57.
- 20 81. A method for inhibiting the activity of MASP-2 by administering to the subject a compound that inhibits expression or activity of MASP-2.
82. The method of claim 81 in which the compound is a MASP-2 anti-sense nucleic acid sequence.
- 25 83. The method of claim 81 comprising administering a compound that inhibits complexing of MBL and MASP-2.
- 30 84. An assay for polymorphisms in the nucleic acid sequence encoding MASP-2.
85. A method of detecting the presence of MASP-2-encoding nucleic acid in a sample, comprising mixing the sample with at least one nucleic acid probe capable of forming a complex with MASP-2-encoding nucleic acid under stringent conditions, and determining whether the probe is bound to sample nucleic acid.
- 35

86. A nucleic acid probe capable of forming a complex with MASP-2-encoding nucleic acid under stringent conditions.
- 5 87. An assay for polymorphisms in the polypeptide sequence comprising MASP-2 or its precursor.
- 10 88. A method for diagnosing a disorder associated with aberrant expression of MASP-2, comprising obtaining a biological sample from a patient and measuring MASP-2 expression in said biological sample, wherein increased or decreased MASP-2 expression in said biological sample compared to a control indicates that said patient suffers from a disorder associated with aberrant expression of MASP-2.
- 15 89. A method for diagnosing a disorder associated with aberrant activity of MASP-2, comprising obtaining a biological sample from a patient and measuring MASP-2 activity in said biological sample, wherein increased or decreased MASP-2 activity in said biological sample compared to a control indicates that said patient suffers from a disorder associated with aberrant activity of MASP-2.
- 20 90. A method of assaying for activity MBL-complexed MASP, the method comprising providing a sample to be assayed and substantially reducing any artifact resulting from activation of the classical complement fixing pathway by conducting the assay in the presence of an ionic strength high enough to effectively reduce activation of the classical complement fixing pathway but not
- 25 so high as to substantially interfere with activity of MBL-complexed MASP.
- 30 91. A method for determining the activity of MASP-2, said method comprising an assay for MASP-2 activity, comprising the steps of
- applying a sample comprising MBL/MASP-2 complexes to a solid phase obtaining a bound complexes,
  - applying at least one complement factor to the complexes,
  - 35 - detecting the amount of cleaved complement factors,

- correlating the amount of cleaved complement factors to the MASP-2 amount, and

- 5        - determining the activity of MASP-2.

92. The method according to claim 91, wherein the solid phase is a mannan coating.

10       93. The method according to any of the claims 91 to 92, wherein the at least one complement factor is a complement factor cleavable by the MBL/MASP-2 complex.

94. The method according to any of the claims 91 to 93, wherein the at least one complement factor is selected from C3, C4, and C5, preferably C4.

15

95. The method according to any of the preceding claims 91 to 94, wherein the cleaved complement factor is detected by means of antibodies directed to the complement factor.

20

96. The method according to any of the preceding claims 91 to 95, wherein activation of the classical complement pathway is inhibited.

97. The method according to claim 96, wherein the activation is inhibited by conducting the assay at high ionic strength.

25

98. The method according to claim 97, wherein the salt concentration is above 0.2 M, such as in the range of from 0.3 M to 10 M, such as from 0.5 M to 5 M, such as from 0.7 M to 2 M, such as from 0.9 M to 2 M, such as about 1.0 M.

30


99. The method according to claim 98, wherein the salt is selected from NaCl, KCl, MgCl<sub>2</sub>, CaCl<sub>2</sub>, NaI, KCl, MgI<sub>2</sub>, CaI<sub>2</sub>, from NaBr, KBr, MgBr<sub>2</sub>, CaBr<sub>2</sub>, Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>, (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, and NH<sub>4</sub>HCO<sub>3</sub>.

35


100.        The method according to any of the claims 91 to 99 for quantitative assay of MASP-2 or MASP-2 activity in biological samples.

1/6

**Figure 1b**



**Figure 1a**




2/6


## Figure 2

MASP-2		C1r/C1s →		TPLGPKWPFVFGRLASPGFPGGEYANDQERRMTLTAPPGYRLRLYTFHDLFLSHLSEYDFVKLSSGAKVLATLGGQESTDTERAPGKDT		90
MASP-1				HTVELNNMFGQIQSPGYPDSYPSDSEVTWNIIVPDGFRILKLYFMHFNLESSYLSEYDYVKVETEDQVLATFGRETDTDTQTPGQEV		87
C1r				SIPIPQKLFGEVTSPLFPKPYPNFETTTVITVPTGYRVLVFPQFDLEPSEGPFYDYVKISADKSKLGRFGQLGSPLGNPPGKKE		87
C1s				EPTMYGEILSPNYPQAYPSEVEKSWDIEVPEGYGIHLVPTHLDIELSENAYDSVQIISGDTEEGRLGQRSSNNPSPIVER		83
				* * * * *		
MASP-2		ECF →		FVSLGSSLDITFRSDYSNEKP FVGFRAFYAARDIDEEQ VAPGEA PTQHHCHNHLGGFYSSRAGYVLHKNKRTSALSS		170
MASP-1				VLSPGSFMSTFRSDFSNEER FTGFAHYMAVDVDEK EREDEE LSCHYCHNYIGGYSSRFGYILHTDHTSRVES		167
C1r				FMSQGNKMLLTFTDPSNEENGITMFKGFLAYYQAVDLDEASRSKSGHEEPQPOHLSCHNYVGGYSSRPGYELQEDRESQARSS		177
C1s				FQVPYNKLQVIFKSDFSNEER FTGFAAYVATDINEET DFVD VPSHPNNFVGGYSSRPPYFLHDDMKMGVNNSS		161
				* * * * *		
MASP-2		C1r/C1s →		GVVFTQRSGLSSPEYPRPYPKLSSSTYSISLEEGFSVILDFV ESFDVET HPETLSPYDFLKIQTDRREHGPFSGKTLPHR IETKS		256
MASP-1				DNLFTQRTGVTSPDFPNPYPKSSSELYTILEEGFMVNLQFE DIFDIED HPEVSPYDYIKIKVGPVKLGPPGGEKAPPE ISTQS		253
C1r				SELYTEASGYISSLEYPRSYPPDLRCHNYSIRVERGLTLHLKFL EPPDIDD HQQVHPYDQLQIYANGKNIGEPGKQRPD LDTSS		263
C1s				GDVFTALIGIASPNYPKPENSRSEYQIRLEKGFQVVVTLRRDFDVEAADSAGNGLDSLFFVAGDRQPGFYSGHGFPGPLNIETKS		250
				* * * * *		
MASP-2		CCP-1 →		NTVTITFVTDESQDHTGKNIHYTSTAQSPYPMAPPN GHVSPVQAKYILKDSFSIFETGYELLQGHLPKSFATAVQKDGSMWRMPFA		345
MASP-1				HSVLILFSDNSGENRGWRLSYRAAGNEPELQPPVH GKIEPSQAKYFFKQVLVSOTGYKVLKDNVEMDTFQIEELKDGTSWENKIPT		342
C1r				NAVDLFFFTDESQDSRGWKLRYTTIIEIKQPKTLDEFTIIONLQPOYQFRDYFIATKQGYQLIEGNQVLHSFATAVQDDGTWHRAMPR		353
C1s				NALDIIFQDILTQKKKGWKLRYHGDPMPEPKEDTPN SVWEPAKAKYVFRDVVQITLQDGFVEVEGRVGATSFYSTQSNKGWNSKLLK		338
				* * * * *		
MASP-2		CCP-2 →		KSIVDGGPPDDLPSGRVEYITGPGVTTYRAVIQVSSSEFTYTM KVNDDGYVSEADGFWTSSKGEKSLFVSEFVGLS ARTT		426
MASP-1				KIVDGRAPGELEHGLITFTSRNNLTYYKSEIKYSQEPFYKML NNNTGIYTSAGGVMMNKVLGRSLPTLFPVGLPKFSRKL		426
C1r				KIKDGGQPRNLPNGDFRYTTIMGVNTYKARIQYVHEPFYKMQTRAGSRESEQGVYTTAQGIWKNEQKGEKIPRSLFVSGKVPMPVEQ		443
C1s				QPVDTGIPESIEGKVE DPESTLFGSVIRYVHEPFYVME NGGGGFYHAGNGSWVNEVLGPFLPKVFPVGVPPREPFEE		419
				* * * * *		
MASP-2		serine protease →		GGRIYGGQKAKPGDFPWQVLILGTTA AGALLYDNWVLTAAH AVYEQKHDA SALLDIRMGTLLKRLSPHYTQAWSEAVFIHEG		507
MASP-1				MARIPNGRPAQKGTTPWIAMLSHLNGQPPCGGSLGSSWIVTAAHCLHQSLEDKDPDLRSDLLSPD FKILQKHWRLEDENEQHLG		515
C1r				RQRIIGGQKAKMGNFPWQVFINIHRG GQALLGDRNLTAAH TLYPKEHBAQSNASLDVFLGHTNVERLMLKLNHP IRRV		523
C1s				KQRIIGGSADILKNFPWQVFDNFWA GQALINEYNVLTAAH VVEGNREPTMYVGSTSVQTSRLAKSKMLT PEHVFIDHC		498
				* * * * *		
MASP-2		YTHDAG		FDNDIALIKLNKVVINSNITPIQLPKREARSFMRDIDDIGTASGWLGTORGFLARNLMYVDIPVDHQRSTAAAYEK		589
MASP-1				VKHTTLHPKYDPNTFENDVALVELLESFVLNAFVMPILP EGPQEGAMVIVSGWQKQLQRFPELMEIEIPVDHSTQKAY		599
C1r				SVHPDYRQDESYN FEGDIALLENSVTLGPNLLFPLP DNDTFYDLGLMGYVSGFGVMEEK IAHDLRFVRLPVANPQAHEN WLR		608
C1s				WKLLEV PEGRTN FDNDIALVRLKDPVKMGPTVSPILPQGTSSDYNLMDGLGLISGWGRTEKRDRAVRLKAARLPVAPLRKPEVKVE		586
				* * * * *		
MASP-2		PPYPRG		SVTANMLAGLESGGKDSERGDSGGALVFLDS ETERWVGGIVSWGSMNGEAGQYGVYTKVINIYIPWIENIISDF		671
MASP-1				APLKK KVTDRMISAGEKEGGKDAESGDSGGPMVTLNR ERGQWYLVGTVSWGQ DGGKIDRYGVVSYIHNKDWIQVTVGRN		680
C1r				GKNRMD VFGNMPAGHPSLKQDASQDGGGVFAVRDP NTDRNVATGIVSWGIGSRG YGFTYKVLNVYDWIKKMEED		688
C1s				KPTADAAYVFTPNMIGAGGEK GMDSSKGDGGGAFVQDFENDKTKFYAAGLVSWGPOGUT YGLYTRVKNYVDWIMKMDQENSTFRED		673
				* * * * *		

### 3/6 Figure 3a




### Figure 3b



4/6

**Figure 4**


**Blot of MBL preparation**



↑  
MASP-1

↑  
MASP-2

**Blot of C1**




↑  
C1s



5/6

Figure 5



6/6

Figure 6

ctctgtgcatttcgggcaagaggtggaagggcacaccATGAGGCTGCTGACCCCTCTGGGCTTCTGTGTGCTCGGTGGCCACCCCTTAGGCCCGAAGT 100  
 M R L L T L L C L L C G S V A T P L G P K 6  
 GGCTGAACCTGTGTTCCGGCGCCTGGCATCCCGCGCTTTCAGCGGAGTATGCCAATGACACGAGCGCGCTGGACCTGACTGCACCCCGCGCTA 200  
 H P E P V F G R L A S P G F P G E Y A N D O E R R W T L T A P P G Y 40  
 CCGCTGCGCTTACTTCAACCACTTCGACCTGGAGCTCTCCCACTCTGCGATACGACTTGTCAAGCTGAGCTCGGGGCGCAAGGTGCTGGCCACG 300  
 R L R L Y F T H F D L E L S R L C E Y D F V X L S S G A K V L A T 73  
 CTGTGCGGCGAGGAGACACAGACACGAGCGCGCGCTGGCAAGGACACTTCTACTGCTGGGCTCTGCGCTGGACATTACCTTCGCTCGGACTACT 400  
 L C G Q E S T D T E R A P G K D T F Y S L G S S L D I T F R S D Y 106  
 CCAACGAGAAGCGCTTACCGCGCTTCAGCGCTTCTATGACGCGGACACATTCAGAGTGCAGGTGGKCCCGGAGAGCGCGCCACCTGCGGACACCA 500  
 S N E K P F T G F E A P Y A A E D I D E C Q V A P G E A P T C D R H 140  
 CCACACCAACCTGGGCGCTTCTACTGCTCTGCGCGCGCAGGCTAGCTCTGCGACGCTAACAGCGTACCTGCTCAGCCCTGTGCTCGCGCCAGGTC 600  
 C H N H L G G F Y C S C R A G Y V L H R N K R T C S A L C S G Q V 173  
 TTCACCCAGAGCTTGGGGAGCTCAGCAGCCCTGAATACCCACGCGCGTATCCCAACTCTCCAGTTCGCTTACAGCATCAGCCCTGGAGGAGCGGCTCA 700  
 F-T Q R S G E L S S P E Y P R P Y P K L S S C T Y S I S L E E G F 206  
 GTGTCTTCTGAGCTTGTGGAGTCCCTTCGATGTGGAGACACCCCTGAAACCTGTGTCCCTACGACTTCTCAAGATTCAAAACAGACAGAGAAGAACA 800  
 S V I L D F V E S F D V E T H P E T L C P Y D L K I Q T D R E E H 240  
 TGGCCCATCTGTGGGAAGACATTGCCCCACAGGATTGAACAAAAAGCAACCGGTGACCATCACTTGTGACAGATGAATCAGGAGACCAACACAGCC 900  
 G P F C G K T L P H R I E T K S N T V T I T F V T D E S G D H T G 273  
 TGAAGATCCACTACACGAGCAGCGCGAGCCTTGGCCCTTATCCGATGGCGCCACCTAATGGCCAGCTTTCACCTGTGCAAGCCAAATACATCTGAAAG 1000  
 W K I H Y T S T A Q P C P Y P M A P P P N G H V S P V Q A K Y I L K 306  
 ACAGCTTCTCCATCTTTTCCGAGACTGGCTATGAGCTTCTGCAAGCTCACTTCCCGCTGAAATCCTTACTGCGCTTGTGACAGATGATCTTGGGA 1100  
 D S F S I F C E T G Y E L L Q G H L P L K S F T A V C Q K D G S W D 340  
 CCGCCCAATCCCGCGTGCAGCATTTGACTGTGGCCCTCTGTGATCTACCCAGTGGCCGAGTGGAGTACATCAGAGCTCTGGAGTGACCACTAC 1200  
 R P M F A C S I V D C G P P D D L P S G R V E Y I T G P G V T T Y 373  
 AAAGCTGTGATTCACTACAGCTGTGAAGAGACCTTCTACCAATGAAGTGAATGATGTAATATATGTGTGTGAGGCTGATGATTCTGGAGAGCTCCA 1300  
 K A V I Q Y S C E E T F Y T N K V N D G K Y V C E A D G F W T S S 406  
 AAGGAGAAAAATCACTCCAGTCTGTGAGCCTGTGTGTGAGTATGAGCCGACAAACAGGAGCGCGTATATATGAGGCGAAAAGGCAAACTCTGTA 1400  
 K G E K S L P V C E F V C G L S A B T T G G R I Y G G Q K A K P G D 440  
 TTTTCTTGGCAAGTCCGATATTAGGTGGAACCAAGCAGGAGGACCTTTATATGACAACTGGGTCTTACAGCTGCTCATGCCCTCTATGAGCAA 1500  
 F P W Q V L I L G G T T A A G A L L Y D N W V L T A A V Y E Q 473  
 AACATGATGATCCGCGCTGGACATTGGAATGGGACCCCTGAAAGACTATCACTCTATTATACACAGCTGCTGCTGAGCTGTTTTTATACATGAAG 1600  
 A H D A S A L D I R M G T L K R L S P H Y T Q A W S E A V F I H E 506  
 GTTATCTCATGATGCTGCTTTCACAAATGACATAGCACTGATTAAATGAATAACAAAGTTGTAATCAGAGCAACATCAGCCCTATTCTGCTGCCAAG 1700  
 G Y T E D A G F D N I A L I K L N N K V V I N S N I T P I C L P R 540  
 AAAAGAAAGCTCAATCTTTATGAGCAACAGTGAATTGCACTGCTGGATCGGGATTAAACCAAAAGGGTTTTCTTGTCTAGAAATCTAATGTATGTC 1800  
 K E A E S F M R T D D I G T A S G W G L T Q R G F L A R N L M Y V 573  
 GACATACCGATTGTTGACCATCAAAATGTACTGTGATATGAAAGCCACCTATCCAGCGGAAGTATACTGCTAACATGCTTTGTGCTGCTTAG 1900  
 D I P I V D H Q K C T A A Y E K P P Y P R G S V T A N M L C A G L 506  
 AAAGTGGCGGCAAGGACAGCTGAGCGGAGCGGCACTGGTTCTAGATAGTGAACAAAGAGGTGTTGTGCGGCAATAGTGTCTGCT 2000  
 E S G G K D S C R G D G G A L V L F L D S E T E R W F V G G I V S W 540  
 GGGTTCATGAATTTGCGGAAAGCAGGTCAATATGAGCTCTACACAAAGTTATTAACTATATCCCTGATCGAGAACATAATTAGTATTTTTAACT 2100  
 G S H N C G E A G Q Y G V Y T K V I N Y I P I E N I I S D F stop 571  
 gsgtgtctgcagtcaggattctctcatcttttagaaatgcctgtggaagacttggcagcagctggctcagagaagattcatcattactgtggacatggca 2200  
 gttgtgtctccagcccaaaaaaacagactccaggtgaggtgtctctctctctccacttgcagttttaaaccagccctacccattgactcaagggagat 2300  
 aaaaacagagagtgacgtctctcttggccacccaggtgaatgtcaactgtctcaattacatttcaacttaaaagccagctctctctctctactgtgt 2400  
 gttggcattctctgtaaactgctgtccatgtctcttgtttttaaactgtctcttattgzaaaaaa 2475

## SEQUENCE LISTING

&lt;110&gt; NatImmune

&lt;120&gt; MASP-2, a complement fixing-enzyme, and uses for it

&lt;130&gt; MASP-2

&lt;140&gt;

&lt;141&gt;

&lt;150&gt; PA 2000 01089

&lt;151&gt; 2001-07-13

&lt;160&gt; 3

&lt;170&gt; PatentIn Ver. 2.1

&lt;210&gt; 1

&lt;211&gt; 41

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 1

Thr Pro Leu Gly Pro Lys Trp Pro Glu Pro Val Phe Gly Arg Leu Ala  
 1 5 10 15

Ser Pro Gly Phe Pro Gly Glu Tyr Ala Asn Asp Gln Glu Arg Arg Trp  
 20 25 30

Thr Leu Thr Ala Pro Pro Gly Tyr Arg  
 35 40

&lt;210&gt; 2

&lt;211&gt; 686

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

Met Arg Leu Leu Thr Leu Leu Gly Leu Leu Cys Gly Ser Val Ala Thr  
 1 5 10 15

Pro Leu Gly Pro Lys Trp Pro Glu Pro Val Phe Gly Arg Leu Ala Ser  
 20 25 30

Pro Gly Phe Pro Gly Glu Tyr Ala Asn Asp Gln Glu Arg Arg Trp Thr  
 35 40 45

Leu Thr Ala Pro Pro Gly Tyr Arg Leu Arg Leu Tyr Phe Thr His Phe  
 50 55 60

Asp Leu Glu Leu Ser His Leu Cys Glu Tyr Asp Phe Val Lys Leu Ser  
 65 70 75 80

Ser Gly Ala Lys Val Leu Ala Thr Leu Cys Gly Gln Glu Ser Thr Asp  
 85 90 95

Thr Glu Arg Ala Pro Gly Lys Asp Thr Phe Tyr Ser Leu Gly Ser Ser

100					105					110					
Leu	Asp	Ile	Thr	Phe	Arg	Ser	Asp	Tyr	Ser	Asn	Glu	Lys	Pro	Phe	Thr
		115					120					125			
Gly	Phe	Glu	Ala	Phe	Tyr	Ala	Ala	Glu	Asp	Ile	Asp	Glu	Cys	Gln	Val
	130					135					140				
Ala	Pro	Gly	Glu	Ala	Pro	Thr	Cys	Asp	His	His	Cys	His	Asn	His	Leu
145					150					155					160
Gly	Gly	Phe	Tyr	Cys	Ser	Cys	Arg	Ala	Gly	Tyr	Val	Leu	His	Arg	Asn
				165					170					175	
Lys	Arg	Thr	Cys	Ser	Ala	Leu	Cys	Ser	Gly	Gln	Val	Phe	Thr	Gln	Arg
			180					185					190		
Ser	Gly	Glu	Leu	Ser	Ser	Pro	Glu	Tyr	Pro	Arg	Pro	Tyr	Pro	Lys	Leu
		195					200					205			
Ser	Ser	Cys	Thr	Tyr	Ser	Ile	Ser	Leu	Glu	Glu	Gly	Phe	Ser	Val	Ile
	210					215					220				
Leu	Asp	Phe	Val	Glu	Ser	Phe	Asp	Val	Glu	Thr	His	Pro	Glu	Thr	Leu
225					230					235					240
Cys	Pro	Tyr	Asp	Phe	Leu	Lys	Ile	Gln	Thr	Asp	Arg	Glu	Glu	His	Gly
				245					250					255	
Pro	Phe	Cys	Gly	Lys	Thr	Leu	Pro	His	Arg	Ile	Glu	Thr	Lys	Ser	Asn
			260					265					270		
Thr	Val	Thr	Ile	Thr	Phe	Val	Thr	Asp	Glu	Ser	Gly	Asp	His	Thr	Gly
		275					280					285			
Trp	Lys	Ile	His	Tyr	Thr	Ser	Thr	Ala	His	Ala	Cys	Pro	Tyr	Pro	Met
	290					295					300				
Ala	Pro	Pro	Asn	Gly	His	Val	Ser	Pro	Val	Gln	Ala	Lys	Tyr	Ile	Leu
305					310					315					320
Lys	Asp	Ser	Phe	Ser	Ile	Phe	Cys	Glu	Thr	Gly	Tyr	Glu	Leu	Leu	Gln
				325					330					335	
Gly	His	Leu	Pro	Leu	Lys	Ser	Phe	Thr	Ala	Val	Cys	Gln	Lys	Asp	Gly
			340					345					350		
Ser	Trp	Asp	Arg	Pro	Met	Pro	Ala	Cys	Ser	Ile	Val	Asp	Cys	Gly	Pro
		355					360					365			
Pro	Asp	Asp	Leu	Pro	Ser	Gly	Arg	Val	Glu	Tyr	Ile	Thr	Gly	Pro	Gly
	370					375					380				
Val	Thr	Thr	Tyr	Lys	Ala	Val	Ile	Gln	Tyr	Ser	Cys	Glu	Glu	Thr	Phe
385					390					395					400
Tyr	Thr	Met	Lys	Val	Asn	Asp	Gly	Lys	Tyr	Val	Cys	Glu	Ala	Asp	Gly
				405					410					415	

Phe Trp Thr Ser Ser Lys Gly Glu Lys Ser Leu Pro Val Cys Glu Pro  
 420 425 430  
 Val Cys Gly Leu Ser Ala Arg Thr Thr Gly Gly Arg Ile Tyr Gly Gly  
 435 440 445  
 Gln Lys Ala Lys Pro Gly Asp Phe Pro Trp Gln Val Leu Ile Leu Gly  
 450 455 460  
 Gly Thr Thr Ala Ala Gly Ala Leu Leu Tyr Asp Asn Trp Val Leu Thr  
 465 470 475 480  
 Ala Ala His Ala Val Tyr Glu Gln Lys His Asp Ala Ser Ala Leu Asp  
 485 490 495  
 Ile Arg Met Gly Thr Leu Lys Arg Leu Ser Pro His Tyr Thr Gln Ala  
 500 505 510  
 Trp Ser Glu Ala Val Phe Ile His Glu Gly Tyr Thr His Asp Ala Gly  
 515 520 525  
 Phe Asp Asn Asp Ile Ala Leu Ile Lys Leu Asn Asn Lys Val Val Ile  
 530 535 540  
 Asn Ser Asn Ile Thr Pro Ile Cys Leu Pro Arg Lys Glu Ala Glu Ser  
 545 550 555 560  
 Phe Met Arg Thr Asp Asp Ile Gly Thr Ala Ser Gly Trp Gly Leu Thr  
 565 570 575  
 Gln Arg Gly Phe Leu Ala Arg Asn Leu Met Tyr Val Asp Ile Pro Ile  
 580 585 590  
 Val Asp His Gln Lys Cys Thr Ala Ala Tyr Glu Lys Pro Pro Tyr Pro  
 595 600 605  
 Arg Gly Ser Val Thr Ala Asn Met Leu Cys Ala Gly Leu Glu Ser Gly  
 610 615 620  
 Gly Lys Asp Ser Cys Arg Gly Asp Ser Gly Gly Ala Leu Val Phe Leu  
 625 630 635 640  
 Asp Ser Glu Thr Glu Arg Trp Phe Val Gly Gly Ile Val Ser Trp Gly  
 645 650 655  
 Ser Met Asn Cys Gly Glu Ala Gly Gln Tyr Gly Val Tyr Thr Lys Val  
 660 665 670  
 Ile Asn Tyr Ile Pro Trp Ile Glu Asn Ile Ile Ser Asp Phe  
 675 680 685

<210> 3  
 <211> 671  
 <212> PRT  
 <213> Homo sapiens

<400> 3  
 Thr Pro Leu Gly Pro Lys Trp Pro Glu Pro Val Phe Gly Arg Leu Ala

1	5	10	15
Ser	Pro Gly Phe	Pro Gly Glu Tyr	Ala Asn Asp Gln Glu Arg Arg Trp
	20	25	30
Thr	Leu Thr Ala	Pro Pro Gly Tyr	Arg Leu Arg Leu Tyr Phe Thr His
	35	40	45
Phe	Asp Leu Glu	Leu Ser His Leu Cys	Glu Tyr Asp Phe Val Lys Leu
	50	55	60
Ser	Ser Gly Ala	Lys Val Leu Ala Thr	Leu Cys Gly Gln Glu Ser Thr
	65	70	75
Asp	Thr Glu Arg	Ala Pro Gly Lys	Asp Thr Phe Tyr Ser Leu Gly Ser
	85	90	95
Ser	Leu Asp Ile	Thr Phe Arg Ser	Asp Tyr Ser Asn Glu Lys Pro Phe
	100	105	110
Thr	Gly Phe Glu	Ala Phe Tyr Ala	Ala Glu Asp Ile Asp Glu Cys Gln
	115	120	125
Val	Ala Pro Gly	Glu Ala Pro Thr	Cys Asp His His Cys His Asn His
	130	135	140
Leu	Gly Gly Phe	Tyr Cys Ser Cys	Arg Ala Gly Tyr Val Leu His Arg
	145	150	155
Asn	Lys Arg Thr	Cys Ser Ala Leu	Cys Ser Gly Gln Val Phe Thr Gln
	165	170	175
Arg	Ser Gly Glu	Leu Ser Ser Pro	Glu Tyr Pro Arg Pro Tyr Pro Lys
	180	185	190
Leu	Ser Ser Cys	Thr Tyr Ser Ile	Ser Leu Glu Glu Gly Phe Ser Val
	195	200	205
Ile	Leu Asp Phe	Val Glu Ser Phe	Asp Val Glu Thr His Pro Glu Thr
	210	215	220
Leu	Cys Pro Tyr	Asp Phe Leu Lys	Ile Gln Thr Asp Arg Glu Glu His
	225	230	235
Gly	Pro Phe Cys	Gly Lys Thr Leu	Pro His Arg Ile Glu Thr Lys Ser
	245	250	255
Asn	Thr Val Thr	Ile Thr Phe Val	Thr Asp Glu Ser Gly Asp His Thr
	260	265	270
Gly	Trp Lys Ile	His Tyr Thr Ser	Thr Ala His Ala Cys Pro Tyr Pro
	275	280	285
Met	Ala Pro Pro	Asn Gly His Val	Ser Pro Val Gln Ala Lys Tyr Ile
	290	295	300
Leu	Lys Asp Ser	Phe Ser Ile Phe	Cys Glu Thr Gly Tyr Glu Leu Leu
	305	310	315
			320

Gln Gly His Leu Pro Leu Lys Ser Phe Thr Ala Val Cys Gln Lys Asp  
 325 330 335  
 Gly Ser Trp Asp Arg Pro Met Pro Ala Cys Ser Ile Val Asp Cys Gly  
 340 345 350  
 Pro Pro Asp Asp Leu Pro Ser Gly Arg Val Glu Tyr Ile Thr Gly Pro  
 355 360 365  
 Gly Val Thr Thr Tyr Lys Ala Val Ile Gln Tyr Ser Cys Glu Glu Thr  
 370 375 380  
 Phe Tyr Thr Met Lys Val Asn Asp Gly Lys Tyr Val Cys Glu Ala Asp  
 385 390 395 400  
 Gly Phe Trp Thr Ser Ser Lys Gly Glu Lys Ser Leu Pro Val Cys Glu  
 405 410 415  
 Pro Val Cys Gly Leu Ser Ala Arg Thr Thr Gly Gly Arg Ile Tyr Gly  
 420 425 430  
 Gly Gln Lys Ala Lys Pro Gly Asp Phe Pro Trp Gln Val Leu Ile Leu  
 435 440 445  
 Gly Gly Thr Thr Ala Ala Gly Ala Leu Leu Tyr Asp Asn Trp Val Leu  
 450 455 460  
 Thr Ala Ala His Ala Val Tyr Glu Gln Lys His Asp Ala Ser Ala Leu  
 465 470 475 480  
 Asp Ile Arg Met Gly Thr Leu Lys Arg Leu Ser Pro His Tyr Thr Gln  
 485 490 495  
 Ala Trp Ser Glu Ala Val Phe Ile His Glu Gly Tyr Thr His Asp Ala  
 500 505 510  
 Gly Phe Asp Asn Asp Ile Ala Leu Ile Lys Leu Asn Asn Lys Val Val  
 515 520 525  
 Ile Asn Ser Asn Ile Thr Pro Ile Cys Leu Pro Arg Lys Glu Ala Glu  
 530 535 540  
 Ser Phe Met Arg Thr Asp Asp Ile Gly Thr Ala Ser Gly Trp Gly Leu  
 545 550 555 560  
 Thr Gln Arg Gly Phe Leu Ala Arg Asn Leu Met Tyr Val Asp Ile Pro  
 565 570 575  
 Ile Val Asp His Gln Lys Cys Thr Ala Ala Tyr Glu Lys Pro Pro Tyr  
 580 585 590  
 Pro Arg Gly Ser Val Thr Ala Asn Met Leu Cys Ala Gly Leu Glu Ser  
 595 600 605  
 Gly Gly Lys Asp Ser Cys Arg Gly Asp Ser Gly Gly Ala Leu Val Phe  
 610 615 620  
 Leu Asp Ser Glu Thr Glu Arg Trp Phe Val Gly Gly Ile Val Ser Trp  
 625 630 635 640

Gly Ser Met Asn Cys Gly Glu Ala Gly Gln Tyr Gly Val Tyr Thr Lys  
645 650 655

Val Ile Asn Tyr Ile Pro Trp Ile Glu Asn Ile Ile Ser Asp Phe  
660 665 670



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**